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SUMMARY
This work examines a variety of clinical and experimental aspects of 
hepatocellular carcinoma (HCC), both in patients with this disease and 
in an animal model of the condition. Most of the studies examine 
areas of therapeutic interest.
Chapter 1
The clinical, prognostic, aetiological and pathological features of a 
series of 50 British HCC patients are detailed. Most patients 
presented in poor clinical condition and with non-specific symptoms. 
Cirrhosis was present in 78% and approximately 40% of patients had 
serological evidence of past or present hepatitis B virus infection. 
Median duration of survival was seven weeks from diagnosis. Only the 
presence or absence of cirrhosis and clinical condition at diagnosis 
affected prognosis. The majority of tumours were of trabecular 
histological pattern and liver cell dysplasia was noted in the 
non-neoplastic liver of 79% of patients.
Chapters 2 and 3
The treatment of HCC is reviewed and a phase II clinical trial of 
treatment with the cytotoxic drug mitozantrone reported. Objective 
responses to mitozantrone treatment were seen in 27% of evaluable 
patients and serious side-effects were rare. Quality of survival on 
treatment was good.
(xii)
Chapter 4
The history of the athymic mouse and the role of this animal in the 
screening of new anti-cancer therapies is briefly discussed. The 
"materials and methods" used in the culture of human HCC cell lines 
and the production of human HCC tumour xenografts are described.
Chapter 5
The effects of human lymphoblastoid interferon (HuIFN-o< [Ly], IFN) on 
the growth of the HCC cell line PLC/PRF/5 were assessed both in vitro 
and in athymic mice with PLC/PRF/5-derived tumour xenografts. In 
vitro, PLC/PRF/5 cells were sensitive to the antiproliferative effects 
of IFN, growth inhibition being noted at concentrations as low as 1.25 
IU/ml, and in vivo, IFN reduced tumour xenograft growth rate and 
prolonged survival in tumour-bearing animals. Further studies 
examining some of the possible mechanisms involved in growth 
inhibition in vivo demonstrated that IFN was capable of inducing the 
enzyme 2,5-oligoadenylic acid synthetase, an inhibitor of protein 
synthesis, in tumour tissue but not in mouse tissue, and that IFN 
enhanced the display of HLA class I glycoproteins on tumour cells.
Chapter 6
The cytotoxic activity of Natural Killer (NK) cells, which are large 
granular mononuclear cells of potential importance in the host defence 
against malignancy, was measured in patients with HCC. Their NK cell 
activity was found to be reduced when compared to that of healthy 
control subjects or patients with cirrhosis alone. IFN, at low 
concentrations, was capable of augmenting the NK cell activity of HCC 
patients when administered both in vitro and in vivo.
(xiii)
Chapter 7
Specimens of normal adult human liver and tumour xenografts derived 
from three human HCC cell lines were examined for the presence of 
nuclear androgen receptors. Receptors were detected in both benign 
and malignant tissue, and at similar concentrations ranging from 
235-550 fMol mg DNA. Castration did not alter significantly the 
subsequent development and growth of HCC tumour xenografts in male 
athymic mice inoculated with cells from the PLC/PRF/5 cell line.
Chapter 8
A monoclonal antibody, K-PLC^, previously produced at the Royal Free
Hospital and reacting with a tumour-associated antigen on the cell
membrane of PLC/PRF/5 cells, was examined for its ability to bind to
HCC cell lines, HCC tumour xenografts, and tumour biopsy specimens
from patients with HCC. Using an indirect immunofluorescence
technique, K-PLC^ produced membrane staining of three HCC cell lines
and positively stained 10 of 11 human HCC biopsy specimens. In vitro, 
125
I-labelled K-PLC^ bound specifically to PLC/PRF/5 cells, and 
antibody binding could be increased by prior incubation of PLC/PRF/5 
cells with high concentrations of human lymphoblastoid interferon.
Athymic mice with PLC/PRF/5-derived tumour xenografts were injected
3.25 125with I-labelled K-PLC^ or I-mouse IgG, sacrificed at various
time intervals, and bound radioactivity then counted in a variety of
organs. Though circulating blood-pool radioactivity was high
125throughout the study period, the amount of I-K-PLC^ was greater in 
the tumour than in any other solid organ studied and tumour:liver 
ratios for K-PLC^ were greater than those for mouse IgG at all time 
points studied.
(xiv)
Chapter 9
In the light of the results of the thesis, recommendations for further 
studies are made.
(xv)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the tumour on which the work for 
this thesis is based. The other less common primary tumours which 
affect the liver, and metastatic liver tumours, are not discussed.
BACKGROUND
HCC, on a global scale, is one of the commonest malignancies in the 
world today (Okuda and Beasley, 1982; World Health Organisation 
Scientific Group, 1983; Cook-Mozaffari and van Rensburg, 1984; Cook, 
1985). There is a pronounced geographic variation in the incidence of 
this tumour, with annual age-adjusted incidence rates ranging from 
less than four per 100,000 in Northern Europe and North America to 
greater than 100 per 100,000 in parts of sub-Saharan Africa and the 
Far East (Waterhouse et al, 1982; Munoz and Linsell, 1982; 
Cook-Mozaffari and van Rensburg, 1984). In some countries, for 
example Mozambique and Taiwan, HCC is the most common cause of cancer 
death, and in China, the most populous country in the world, HCC is 
the third most frequently observed cancer (Okuda and Beasley, 1982; 
Munoz and Linsell, 1982). HCC incidence rates increase with age in 
all parts of the world but the onset of disease tends to be earlier in 
high incidence areas. In parts of Africa in particular, HCC is a 
common cause of cancer death in young adults (Munoz and Linsell,
1982).
There are also geographic variations in the clinical presentation and 
natural history of HCC, though in all regions of the world the 
prognosis for HCC patients is poor (Okuda et al, 1984). In high 
incidence areas HCC behaves particularly aggressively and patients
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seldom survive more than three months from the time of diagnosis (Kew 
and Geddes, 1982; Nagasue et al, 1984; Okuda et al, 1984; Falkson et 
al, 1986).
The treatment of HCC is unsatisfactory. As the tumour most often 
arises in a cirrhotic liver, and because it is often widespread 
throughout the liver at the time of diagnosis, surgical resection, the 
only realistic hope of cure, is usually not possible (Guest and 
Blumgart, 1987). Currently available cytotoxic agents unfortunately 
have only limited activity. Most published response rates are less 
than 20%-30%, and duration of response is usually disappointingly 
short (Forbes and Williams, 1987). In addition, the toxicity of 
chemotherapy treatment can be substantial and is capable of 
diminishing the quality of life of its recipients.
NEW DEVELOPMENTS
In recent years important advances in a variety of the biomedical 
sciences have occurred, which may in the near future help to dispel 
some of the gloom usually attached to the subject of HCC.
Epidemiological studies (Szmuness, 1978; Beasley et al, 1981; Beasley, 
1982) and the application of the new techniques of molecular biology 
(Brechot et al, 1980; Shafritz and Kew, 1981; Br^chot et al, 1982a) 
have shown a strong association between hepatitis B virus (HBV) 
infection and HCC development. Indeed, the World Health Organisation 
(World Health Organisation Scientific Group, 1983) estimate that 80% 
of all HCCs world-wide may be attributable to HBV infection, and it is 
this association which predominantly accounts for the marked
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geographic variation in HCC incidence previously discussed. Recent 
reviews have detailed the possible molecular mechanisms whereby HBV 
infection may ultimately lead to HCC development (Sherman and 
Shafritz, 1984; Bassendine, 1987; Rogler et al, 1987). It is however 
also possible that HBV infection leads to HCC development indirectly 
via the production of cirrhosis (Zaman et al, 1985; Johnson and 
Williams, 1987), and it remains to be shown conclusively that the HBV 
is truly oncogenic. Bassendine (1987) has also outlined the other 
important aetiological factors in HCC development, and has emphasised 
the complex way in which all factors, including HBV infection, may 
interact to result in hepatic carcinogenesis.
It is now possible to protect against HBV infection by immunisation.
In areas which are endemic for HBV infection (and hence HCC), most 
infections are acquired in the perinatal period or in early childhood 
(Beasley, 1982; World Health Organisation Scientific Group, 1983; 
Beasley and Hwang, 1984; Hsu et al, 1986). Indeed, in Taiwan and 
other parts of Asia, 40% of all chronic HBV carriers are thought to 
become infected in the perinatal period (Beasley, 1982). Programmes 
of combined passive and active immunisation against the HBV, begun 
shortly after birth, have been shown to protect against subsequent HBV 
infection (Beasley et al, 1983; Lo et al, 1985; Stevens et al, 1985; 
Zanetti et al, 1986). If such programmes were instituted in endemic 
areas, the incidence of chronic HBV infection in the population would 
fall, and whatever the mechanisms whereby HBV infection results in HCC 
development, this should eventually lead to a dramatic reduction in 
HCC incidence. Such vaccination programmes are currently too 
expensive for most countries where HBV infection is endemic to adopt, 
but in the near future chemically synthesised polypeptide vaccines and
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vaccines produced by recombinant DNA technology may be widely 
available, and these should be much cheaper than currently available 
plasma-derived vaccines (Zuckerman, 1985).
The exciting prospect of reducing HCC incidence rates through mass 
vaccination of new-born infants against HBV infection is still some 
decades away and in the meantime new methods are needed both for 
diagnosing HCC at an early stage when curative surgery may be 
possible, and for treating patients with inoperable tumours.
With the advent of sensitive radioimmunoassays (RIAs) for the 
detection of serum alphafoetoprotein (AFP) and the development of 
real-time ultrasonography, it is now possible to non-invasively screen 
at-risk populations for HCC development. This subject has recently 
been critically examined by Okuda (1986). While many important 
questions on population screening for HCC remain to be answered, it is 
clear that the combined use of serial serum AFP measurements and 
repeated real-time hepatic ultrasonography represents a major advance 
in the management of Asian patients with chronic liver diseases, as it 
allows the early detection of small asymptomatic HCCs at a stage when 
surgical resection is frequently still possible (Shinagawa et al,
1984; Liaw et al, 1986). This combined approach appears better than 
AFP screening alone, as small HCCs often do not produce detectable 
levels of serum AFP (Shinagawa et al, 1984; Kobayashi et al, 1985;
Liaw et al, 1986; Ebara et al, 1986) and so may be missed if AFP alone 
is used for screening. AFP screeing has been very disappointing in 
the black African population (Purves, 1976), but the value of combined 
AFP and ultrasound screening remains to be determined, both in this 
setting and in low HCC incidence areas such as Europe.
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More effective and less toxic therapies are needed for inoperable HCC 
patients, who, for the foreseeable future, will continue to constitute 
the majority of the HCC population. Several novel modes of cancer 
therapy now exist whose role in HCC treatment remains to be 
determined. The interferons (IFNs) are now being extensively 
investigated in the treatment of a variety of malignancies (Borden, 
1984; Krown, 1986; Golomb, 1986). IFNs possess a variety of potent 
immunomodulatory and antiproliferative properties (Gresser and Tovey, 
1978; Borden and Ball, 1981; Stiehm et al, 1982) which make them of 
potential great importance as anti-cancer agents. Earlier problems of 
lack of availability have been overcome, as many IFNs are now produced 
relatively easily by recombinant DNA technology and are now available 
for clinical study. The production of anti-tumour monoclonal 
antibodies probably represents the most exciting new development in 
Clinical Oncology of the last decade. These agents are highly 
specific, easily and accurately reproduced in bulk, and may enable the 
targeting of radio-isotopes, cytotoxic drugs and potent cellular 
toxins to tumour cells. Monoclonal antibodies are now being 
extensively investigated as potential immunodiagnostic and 
immunotherapeutic agents (Sikora et al, 1984; Dillman and Royston, 
1984; Baldwin and Byers, 1985; Morgan and Foons, 1986; Baldwin and 
Byers, 1986). Monoclonal antibodies have now been produced to 
antigens on HCC cell lines (Carlson et al, 1985; Shouval et al, 1985; 
Hu et al, 1986; Wiedmann et al, in press) and should soon be available 
in sufficient quantity for evaluation in clinical trials.
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THE THESIS
As HCC is relatively rare in this country, and because there is a 
pronounced geographic variation in the natural history of this tumour, 
I have begun the thesis with a detailed analysis of the clinical, 
prognostic, aetiological and pathological features of British HCC 
patients. I have then reviewed the generally disappointing current 
status of treatment for HCC and reported on a phase II clinical trial 
examining the effects of a new anthracenedione, mitozantrone, in HCC 
treatment. The observed response rate of 27%, while slightly better 
than most published results with single agent cytotoxic therapies, was 
disappointing and clearly indicates the need for new approaches to HCC 
diagnosis and treatment.
In an animal model of HCC I therefore subsequently set out to explore 
several potential new methods for therapy and diagnosis. In view of 
the then recent findings of androgen receptors in HCC tumour specimens 
(Iqbal et al, 1983), the effects of androgenic ablation on HCC growth 
were studied, and in the light of the recent developments previously 
discussed, the role of IFNs and anti-HCC monoclonal antibodies in HCC 
treatment and diagnosis were examined.
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CHAPTER ONE
HEPATOCELLULAR CARCINOMA: CLINICAL, AETIOLOGICAL 
AND PATHOLOGICAL FEATURES IN BRITISH PATIENTS
8
ABSTRACT
The clinical, prognostic, aetiological and pathological features of 50 
consecutive British patients with hepatocellular carcinoma (HCC) have 
been examined. Presenting symptoms were often vague, and patients 
were generally in poor condition, ascites and jaundice often being 
present at diagnosis. The median duration of survival from diagnosis 
was only seven weeks. Only initial performance grade and the presence 
or absence of cirrhosis significantly affected prognosis. Serum 
alphafoetoprotein was positive by counter-immune electrophoresis in 
only 40% of patients, but 76% were positive when radioimmunoassay was 
used. Cirrhosis was present in 39 patients (78%) and was usually 
cryptogenic (13), hepatitis B virus (HBV) - related (9) or alcoholic 
(7) in origin. Serum HBsAg was detected in 10 patients (20%), and of 
the remainder, 21% had serological evidence of past HBV exposure.
None of nine serum HBsAg negative tumour specimens had detectable 
HBV-DNA integration into the tumour cell genome. Liver cell dysplasia 
was noted in 53% of patients with liver biopsies predating the 
diagnosis of HCC, and in 79% of biopsies taken at the time of HCC 
diagnosis. The commonest histological pattern was trabecular (70%). 
Other forms were rare; the fibrolamellar pattern was only seen in two 
patients.
In British patients, HCC is usually diagnosed late and is usually 
associated with established cirrhosis. It is rapidly fatal, 
particularly in cirrhotic patients and in those with poor initial 
performance score. In 40% it is associated with serological evidence 
of past or present HBV infection. The relationship between liver cell 
dysplasia and the development of HCC merits further study.
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INTRODUCTION
As previously mentioned, HCC is an uncommon cancer in Northern Europe 
and North America but is frequently seen in sub-Saharan Africa and the 
Far East. The clinical features in high incidence areas are well 
described (Lai et al, 1981; Kew and Geddes, 1982; The Liver Cancer 
Study Group of Japan, 1984). HCC, as it is seen in the United Kingdom 
however, often seems to be diagnosed late, and most patients die 
within a few weeks of diagnosis. A variety of pertinent features in 
50 consecutive British patients with histologically proven HCC have 
therefore been analysed in order to determine whether some common 
presenting clinical features may suggest HCC development, and whether 
some simple clinical and laboratory parameters may be of prognostic 
value.
Possible aetiological factors have also been examined. Using 
serological radioimmunoassays and radiolabelled DNA probes to detect 
viral DNA in tumour tissue, the relationship between chronic HBV 
infection and HCC has been particularly studied. Finally, hepatic 
histology has been reviewed.
PATIENTS AND METHODS
All patients were seen at the Royal Free Hospital, London, between 
January 1978 and December 1984. Forty-one patients (82%) were born in 
Britain and the remaining nine patients (18%), were immigrants (one 
from Africa, two from Asia, two from the Far East and three from the 
West Indies). Information was available on age, sex, presenting 
symptoms, performance status (WHO, 1979), physical signs, presenting
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haematological and biochemical parameters, the results of hepatic 
imaging techniques, duration of survival,and the cause of death.
Serum was analysed for alphafoetoprotein (AFP) by radioimmunoassay
(RIA) (Hoechst Laboratories, UK) and counter-immune electrophoresis
(CIEP). Carcinoembryonic antigen (CEA) concentration was measured by
RIA (Abbot Laboratories, UK). Sera were tested for HBsAg, HBsAb and
HBcAb using commercially available RIAs (all Abbot Laboratories, UK).
HBsAg positive sera were analysed for HBeAg and HBeAb (Abbot) and also
for serum HBV-DNA, using a modification (Karayiannis et al, 1985) of
the dot hybridisation technique (Weller et al, 1982). In 10 patients
tumour tissue was available for analysis of HBV-DNA sequences by
32southern blotting and hybridisation to a ( P) HBV-DNA probe 
(Monjardino et al, 1982; Fowler et al, 1984).
Cirrhosis was diagnosed by histological examination of non-tumour 
tissue, and the aetiology defined on clinical, serological and 
histological grounds (see below). Liver cell dysplasia (Anthony et 
al, 1973) was sought in all biopsy specimens, including specimens 
pre-dating the development of HCC. The histological and cytological 
variants of HCC were characterised (Anthony, 1987).
Statistical analyses were performed using the Chi-squared test with 
Yates correction and the log-rank test as appropriate. Survival 
curves were produced by the Kaplan-Meier method.
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RESULTS
There were 37 men and 13 women (male:female, 2.8:1). The median age 
was 58 years (range 16-77 years); 12 patients (23%) were less than 40 
years old.
Symptoms and physical signs at presentation
In four patients the diagnosis of HCC was not suspected antemortem but 
was made at autopsy. In two patients the diagnosis was made while the 
patient was asymptomatic; one at cholecystectomy, and the other while 
undergoing routine liver biopsy for assessment of primary biliary 
cirrhosis (PBC). The major presenting symptoms in the remaining 46 
patients were malaise (70%), anorexia (60%) and abdominal pain (55%) 
(Table 1 (i)). Pain was usually in the right hypochondrium or 
epigastrium, and of mild to moderate severity. It was chronic and no 
patient presented as an acute emergency due to tumour rupture. 
Abdominal swelling, either due to ascites or to a palpable tumour 
mass, was noted by 37% of patients, and 18% presented either with 
jaundice or gastrointestinal bleeding, the latter always proven by 
endoscopy to be due to variceal rupture.
The presenting performance status of the 46 patients diagnosed in life 
was graded using World Health Organisation (WHO) criteria (WHO, 1979). 
Only five (11%) patients were unrestricted in normal activities and 
therefore in the grade 0 category. Most patients fell into the grade 
1 category (33%) while 22% and 26% respectively fell into grades 2 and 
3. Four patients (8%) were completely disabled, bed-bound and unable 
to perform any self-care, and therefore of grade 4 status.
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Table 1 (i)
PRESENTING SYMPTOMS OF HEPATOCELLULAR CARCINOMA IN BRITISH PATIENTS.
Symptom % with symptom
Malaise 70
Anorexia 60
Abdominal pain 55
Weight loss 47
Diffuse abdominal swelling 27
Jaundice 18
Gastrointestinal bleeding 18
Pruritis 12
Palpable mass 10
Ankle oedema 10
Cough or dyspnoea 6
Deep vein thrombosis 4
No symptoms 4
Fever 2
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The physical signs most commonly seen at presentation are listed in 
Table 1 (ii). In three of the 46 patients tense ascites rendered 
abdominal palpation impossible. Hepatomegaly was noted in 40 (93%) of 
the remaining 43 patients. The liver was invariably hard and in 20% 
was tender. An arterial bruit was heard over the enlarged liver in 
three patients (7.5%). Ascites was detectable in 43%. It was usually 
of mild or moderate severity but in five patients (11%) demanded 
immediate paracentesis. Splenomegaly was noted in 25%, all cases 
being cirrhotic. Spider naevi were seen in 35% of patients and 
jaundice noted in a similar proportion. Hepatic encephalopathy was 
noted in seven patients (15%), being of grade I severity in six and 
grade II in the other. In two patients the encephalopathy was 
ascribed to gastrointestinal bleeding and in five was thought to 
represent hepatocellular failure.
Standard haematological and biochemical tests (Tables 1 (iii) & 1 
(iv))
The erythrocyte sedimentation rate (ESR) was abnormal in 27 of the 32 
patients tested, five patients (16%) having values greater than 100 mm 
in the first hour. The mean haemoglobin concentration was 12.7 g/dl. 
Three of the 46 patients (6.5%) had haemoglobin values above the upper 
limit of normal in the absence of transfusion, but none had a raised 
haematocrit. Five patients (11%) had a haemoglobin concentration less 
than 10 g/dl at presentation, three of whom had recent 
gastrointestinal bleeding. Prothrombin time was abnormal in 38 of 44 
patients, the mean prolongation being almost four seconds. One 
patient, who had no initial clotting studies, developed small 
intestinal venous thrombosis, requiring surgery and subsequent 
anticoagulant therapy.
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Table 1 (ii)
MOST COMMON PRESENTING PHYSICAL SIGNS IN BRITISH PATIENTS WITH 
HEPATOCELLULAR CARCINOMA.
Sign % with sign
Hepatomegaly 93
- % with tenderness 20
- % with bruit 7.5
Ascites 43
Splenomegaly 25
Jaundice 35
Spider naevi 35
Encephalopathy 15
15
A single biochemical abnormality in liver function tests was seen in 
four patients (9%); three showed a raised serum alkaline phosphatase 
concentration, and one an increase in serum aspartate transaminase. 
Among the remaining patients, no particular pattern (i.e. 'hepatitic' 
or 'cholestatic') predominated. Serum aspartate transaminase and 
alkaline phosphatase were each elevated in 90% of patients. At 
presentation 76% of patients showed a raised serum bilirubin 
concentration, the level in 17 (37%) exceeding 50 jjmol/1. The mean 
serum albumin concentration was 35 g/1, with 24% of patients having 
levels less than 30 g/1. Six of 45 patients (13%) had raised 
corrected serum calcium levels. No patient had obvious bone 
metastases and none had symptomatic hypercalcaemia. The serum 
phosphate concentration was reduced in only one of these patients, 
suggesting possible hyperparathyroidism. Random plasma glucose 
concentrations were measured at presentation in 35 subjects, and none 
had evidence of hypoglycaemia. Clinical hypoglycaemia was not a 
problem subsequently.
Presenting serum AFP and CEA concentrations
AFP was measured in the serum by CIEP (lower limit of sensitivity 
around 500 IU/ml) (Eleftheriou et al, 1977) in all patients, and by 
RIA (lower limit of sensitivity <10 IU/ml) in 42 patients. Serum AFP 
was positive by CIEP in 20 patients (40%) and negative in 30 (60%). A 
serum AFP > 10 IU/ml was detected by RIA in 32 of the 42 patients 
tested (76%). The presence or absence of either cirrhosis or serum 
HBsAg had no effect on AFP positivity rates when measured by CIEP 
(Yates corrected Chi-squared test; p>0.05).
16
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Serum CEA concentrations were measured in 21 HCC patients at 
diagnosis. Only three (14%) had raised levels, and in only one 
patient was CEA concentration in the 'tumour range' of greater than 
20 jag/1.
Hepatic imaging techniques
An isotope liver scan (using technetium sulphur colloid) was performed 
in 27 patients. Generalised patchy and reduced uptake of radiocolloid 
was reported in 12 patients (44%). Definite filling defects, 
indicating space occupying lesions, were seen in the livers of 20 of 
the 27 patients (74%). In six patients (22%) patchy uptake of 
radiocolloid precluded a definite diagnosis of hepatic filling defects 
and in the remaining patient (4%) a normal scan was reported. Coeliac 
or selective hepatic angiography was performed in 30 patients. Tumour 
circulation was noted in 29 patients (97%) and in only one patient was 
the hepatic vasculature reported as normal. Abdominal CT scan, with 
and without intravenous contrast enhancement, showed hepatic filling 
defects in 23 of the 24 (96%) patients in whom it was performed, and 
was frequently used in order to selectively target biopsy needles into 
the filling defects.
Hepatocellular carcinoma: aetiology and relationship to cirrhosis
(Table 1(v))
In 39 patients HCC was associated with underlying cirrhosis (78%). In 
six patients (12%) the liver was non-cirrhotic and in five patients 
(10%) the state of the underlying non-malignant liver was not known.
The aetiology of the underlying cirrhosis was classified as follows 
Alcoholic cirrhosis, defined as the presence of cirrhosis in a subject
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with a regular alcohol consumption of >80g per day and/or hepatic 
histological features compatible with alcohol abuse (Scheuer, 1980), 
was present in 18%. Cryptogenic cirrhosis, diagnosed in serum HBsAg 
negative subjects with no history of alcohol abuse, and who had no 
autoantibodies (anti-nuclear factor (ANF) < 1:40 and smooth muscle 
antibody (SMA) < 1:40) or histopathological features characteristic of 
other liver diseases, was observed in 33%. Cirrhosis associated with 
auto-immune chronic active hepatitis, diagnosed in the presence of an 
ANF or SMA ^1:40 was present in 8%, and cirrhosis associated with 
HBV, diagnosed if serum HBsAg was detected by RIA, was seen in 23%. 
Other types of cirrhosis were diagnosed on histological features 
(Scheuer, 1980). In the group of non-cirrhotic patients, and in those
where the state of the underlying non-malignant liver was not known,
usually no recognised aetiological factor could be detected. Two 
tumours however arose in young women in relationship to pregnancy, one 
becoming apparent in the third trimester of pregnancy and the other 
six months after a normal full-term pregnancy.
HCC: relationship to HBV infection (Table 1 (vi))
Ten of 50 patients were positive for serum HBsAg. Of these patients 
nine were tested for HBeAg and HBeAb, and seven for serum HBV-DNA 
sequences. Seven patients were positive for HBeAb and negative for 
HBeAg and two were positive for HBeAg and negative for HBeAb. Serum 
HBV-DNA was detectable in three of the seven patients examined, two 
being HBeAb positive. Thirty-three of the 40 patients negative for 
serum HBsAg were tested for both HBsAb and HBeAb. Twenty-six patients 
(79%) had no serological evidence of past infection with HBV, six
(18%) had both antibodies, and one patient (3%) had HBeAb alone. The
distribution of HBV antibodies between the various types of liver
20
Table 1 (v)
AETIOLOGY OF UNDERLYING LIVER DISEASE IN THE 39 HCC PATIENTS WITH 
CIRRHOSIS.
Aetiology of cirrhosis N q.*o
Cryptogenic 13 33
HBsAg +ve 9 23
Alcoholic 7 18
Primary Biliary Cirrhosis 4 10
Auto-immune 3 8
Haemochromatosis 2 5
oc1-antitrypsin deficiency 1 3
21
Table 1 (vi)
HBeAg, ANTI-HBe AND SERUM HBV-DNA STATUS OF NINE SERUM HBsAg POSITIVE 
HCC PATIENTS.
anti-HBe serum HBV-DNAHBeAg
NT
NT
NT = not tested
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disease encountered in the study population is shown in Table 1 (vii). 
Amongst those patients with serum HBsAg negative cirrhosis, 
serological evidence of past HBV infection was only seen in those with 
cryptogenic (four of 11 tested) or alcoholic cirrhosis (two of five 
tested).
Nine patients, all serum HBsAg negative but two with serological 
evidence of past HBV infection, had tumour specimens available for 
HBV-DNA analysis. No patient had evidence of episomal or integrated 
HBV-DNA sequences.
Cause of Death, duration of survival, and prognostic factors in HCC 
Thirty-three of the 46 patients diagnosed in life received 
chemotherapy, usually with either doxorubicin or mitozantrone. Nine 
patients (20%) were considered too ill for any form of treatment, and 
only four patients (9%) were considered suitable for tumour resection. 
By the end of February 1985, 37 of the 46 patients had died, six were 
still alive (median duration of survival to date 60 weeks from 
diagnosis, range 12-120 weeks) and three had been lost to follow-up. 
The causes of death in HCC patients are listed in Table 1 (viii). The 
majority of patients (20/37, 54%) died of disease progression, shown 
by increasing hepatocellular failure and generalised wasting.
Thirteen patients (35%) died from variceal haemorrhage. Other causes 
of death were unusual, and no patient died of tumour rupture.
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Table 1 (vii)
DISTRIBUTION OF HBV ANTIBODIES AMONGST SERUM HBsAg NEGATIVE HCC 
PATIENTS.
State of non-malignant 
liver
Total No 
in study
No
tested
HBV antibodies
Present* Absent
Cryptogenic cirrhosis 13 11 4 7
Alcoholic cirrhosis 7 5 2 3
Primary biliary cirrhosis 4 4 0 4
Auto-immune type cirrhosis 3 3 0 3
Haemochromatosis 2 2 0 2
o< 1-antitrypsin deficiency 1 1 0 1
Normal 6 5 1 4
Not known 4 2 0 2
*anti-HBc alone or anti-HBe and anti-HBs
24
Table 1 (viii)
CAUSES OF DEATH IN HEPATOCELLULAR CARCINOMA.
Cause N %
Disease progression 20 54
Variceal haemorrhage 13 35
Treatment related 3 8
Unrelated to HCC 1 3
25
The median duration of survival of all patients diagnosed in life was 
seven weeks from diagnosis (Figure 1 (i)). By using the log-rank test 
to compare survival curves, the effects on survival duration of age 
(greater or less than 50 years), sex, serum HBsAg, serum AFP (positive 
or negative by CIEP), initial performance status (WHO grades 0 and 1 v 
WHO grades 2-4) and cirrhosis were studied. Only the presence or 
absence of cirrhosis (p = 0.002, Figure 1 (ii)) and initial 
performance status (p = 0.0001, Figure 1 (iii)) had prognostic value.
Histopathological features
Nineteen of the 50 patients had had liver biopsies (in 13 single and 
in six multiple) pre-dating the histological diagnosis of HCC. Liver 
cell dysplasia was noted in the biopsies of 10 of these 19 patients 
(53%) (Figure 1 (iv)). The median time interval between the 
observation of liver cell dysplasia and the diagnosis of HCC was 37.5 
months (range one day - 15.5 years). In the 50 liver specimens 
diagnostic of HCC, non-malignant liver was also seen in 38 cases, and 
of these, liver cell dysplasia was present in non-tumorous areas in 30 
patients (79%). No significant differences (Yates corrected 
Chi-squared test) could be found in the overall observed frequency of 
liver cell dysplasia between HBsAg positive and negative patients (8/9 
(89%) and 28/36 (78%) respectively) and between cirrhotic and 
non-cirrhotic patients (30/39 (77%) and 4/6 (66%) respectively).
The histological patterns and cytological variants of HCC observed are 
listed in Table 1 (ix). The trabecular histological form occurred in 
35 of 50 patients (70%). Tumours with this pattern were usually 
moderately or well differentiated (Edmondson, 1958) and of the
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Figure 1 (i)
KAPLAN-MEIER SURVIVAL CURVE OF THE 46 HCC PATIENTS DIAGNOSED 
ANTE-MORTEM. Duration of survival was calculated from the time of HCC 
diagnosis.
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Figure 1 (iii)
KAPLAN-MEIR SURVIVAL CURVES OF HCC PATIENTS OF VARYING INITIAL WHO 
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Figure 1 (iv)
LIVER CELL DYSPLASIA. Hepatocytes are of variable size and their 
nuclei are enlarged, irregular and hyperchromatic (haematoxylin and 
eosin) x 40.
Ta
bl
e 
1 
(i
x)
H
Z
<3M
pi
<3
>
<ut—)
o
oz
oH
X
CJ
wZ
pa<1M
pmM
cn
cn
<3
Zo
z
z
p
wXM
a
o
H
sc
pmpi
o
ao
w
z
Pm
Z
Zwu
Pi
<3w
zu
cj
H
S
Pm
W
EC
CO
CO
vO
CM
uo
CO
CM CO
Jm <3
cO ^ CU
iH JM »—i
Z 3 CO Z
<3 »0 tH CO
CJ U P3 03 fH •H
M  ■ CO CO *H CO <v M-4
o I-1 *H O 3 s •H
o z S bo e O CO CO
►J Pi o o <u Z fH CO
o  w (U 03 03 Sm 03 O co
H H z E3 <3 P <u u iH
c/3 H CO <D •H z CJ
M  <3 (M CO y •H •H c
EC Pm H Pm C/3 S Pm z
27
hepatocytic cytological variant. Fibrolamellar carcinoma, which has 
been associated with a good prognosis (Berman et al, 1980), was seen 
in only two patients, both young adults (ages 16 and 26) with 
non-cirrhotic livers. Four carcinomas could not be classified. In 
two the tumour specimen was either too small or too necrotic, and in 
the other two patients the histological pattern observed could not be 
matched with any of the categories described by Anthony (1987). One 
of these tumours consisted of a mixture of hepatocellular and 
duct-like elements in which the former displayed trabecular, acinar 
and scirrhous areas, and in the other tumour, trabecular, acinar and 
scirrhous areas were once again noted, in a tumour specimen which was 
mostly necrotic. Bile secretion, which is considered pathognomonic of 
HCC (Anthony, 1987), was observed in 21 tumours (44%), the majority 
(16/21) being of trabecular pattern.
DISCUSSION
This series provides the most detailed aetiological, 
clinicopathological and prognostic analysis so far undertaken on 
purely British HCC patients.
The male predominance and the age distribution of HCC patients is 
similar to that reported from other low incidence areas (Ihde et al, 
1974; MacSween, 1974; Johnson et al, 1978a; Chlebowski et al, 1984a) 
and from recent series from the Far East (The Liver Cancer Study Group 
of Japan, 1984; Lin et al, 1984), though the male:female ratio of 
2.8:1 is lower than that previously reported for the U.K. (MacSween, 
1974; Johnson et al, 1978a). The cause of this difference is unclear
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and may simply reflect differing referral patterns between the 
centres. It appears to be unrelated to oral contraceptive usage as 
only four of the women were in the reproductive age group, and only 
two had used oral contraceptives. Though HCC in low incidence areas 
is often considered a tumour of older people, approximately a quarter 
of British patients were under the age of 40 years at diagnosis.
The presenting symptoms of British HCC patients were similar to those 
previously reported from the United Kingdom (MacSween, 1974), North 
America (Chlebowski et al, 1984a), and the Far East (The Liver Cancer 
Study Group of Japan, 1984; Nagasue et al, 1984). Symptoms were 
generally non-specific and of little diagnostic value. However, upper 
abdominal pain, particularly in the right hypochondrium, was a 
presenting feature in 55% of patients, and this symptom, in an at-risk 
patient, should arouse the suspicion of HCC development. Presentation 
as an acute abdominal catastrophe due to tumour rupture, although 
found in 10% of the South African black HCC population (Kew and 
Geddes, 1982), was not observed. Hepatomegaly, ascites and jaundice 
were the most common physical signs. The liver was usually very firm 
and often tender, but a hepatic bruit, advocated as a common physical 
sign in HCC, even in Britain (Kew et al, 1971), occurred in only 7.5% 
of patients.
Clinical condition at diagnosis was often poor, and 34% of patients 
were of WHO performance grade 3 or worse on presentation. Thus 
British HCC patients are often diagnosed late. To prevent this, the 
screening of at-risk populations for the early development of HCC is 
often advocated, whether this be by serial serum AFP measurements (for 
review see Warnes and Smith, 1987) or ultrasonic liver scanning
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(Shinagawa et al, 1984; Liaw et al, 1986). However, our data suggest 
that screening programmes would have a limited impact on the course of 
the disease in this country, as 46% of patients presented de novo with 
established HCC and without previously diagnosed chronic liver 
disease, and so would not have been included in any screening 
programme.
Standard haematological and biochemical tests were often abnormal but 
showed no specific diagnostic pattern. Para-neoplastic phenomena of 
HCC (Margolis and Homey, 1972; Kew and Dusheiko, 1981) were uncommon. 
At diagnosis, serum AFP concentration was elevated in 76% and 40% of 
patients respectively when measured by RIA and by the less sensitive 
CIEP technique. These results are similar to those of other series 
from low incidence areas (Johnson et al, 1978b; Kew and Newberne, 
1982). An AFP concentration of greater than 1000 IU/ml, often 
considered diagnostic of HCC (Johnson et al, 1978b), was found in 38%. 
As noted previously (Melia et al, 1981a), the measurement of serum CEA 
was of no diagnostic help.
Hepatic angiography and CT scanning proved to be highly sensitive and 
equally effective diagnostic techniques. In addition hepatic 
angiography provided useful information in determining tumour 
resectability and portal vein invasion by tumour, and allowed arterial 
embolisation of tumour masses and hepatic arterial chemotherapy if 
desired. Isotope liver scanning, as previously noted (Kew et al,
1971; Bryan et al, 1977), was less sensitive, demonstrating hepatic 
filling defects in approximately 75% of patients.
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The majority of HCCs arose in a cirrhotic liver. This finding agrees 
with results from other geographic regions (Kew and Popper, 1984).
The percentage observed (78% of the total series and 87% of the series 
in whom the state of the underlying non-malignant liver could be fully 
assessed) is similar to that previously reported for largely British 
subjects (Sharpstone et al, 1972; MacSween, 1974; Johnson et al,
1978a). The most commonly observed types of cirrhosis were 
cryptogenic, HBsAg positive and alcoholic. In each type there was a 
marked male predominance (cryptogenic cirrhosis: 11 of 13; HBsAg 
positive cirrhosis: nine of nine; alcoholic cirrhosis: six of seven), 
and of the serum HBsAg negative types of cirrhosis, only those of 
cryptogenic or alcoholic types showed serological evidence of past HBV 
infection. The propensity of cryptogenic, alcoholic and serum HBsAg 
positive cirrhotic patients to develop HCC is well described (MacSween 
and Scott, 1973; Kew and Popper, 1984). The small number of patients 
with haemochromatosis and HCC in the current study probably reflects 
the relative rarity of this condition in the Royal Free Hospital 
patient population.
Approximately 20% of British HCC patients were found to have a 
positive serum HBsAg, and in the remainder positive tests for HBsAb 
and/or HBcAb were found in 21%. These findings are in broad agreement 
with those of Bassendine et al (1979). However, in contrast to the 
findings of Brechot et al (1982a, 1983b), detectable HBV-DNA 
integration into the tumour cell genome of serum HBsAg negative 
patients could not be found, and it is therefore difficult to 
implicate the HBV in the development of tumours in this group, which 
comprise the majority of British patients. As has been previously
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suggested (Fowler et al, 1986), it is possible that in these patients 
HBV-DNA integration may have occurred at the onset of malignant 
transformation and that subsequently integrated sequences have become 
undetectable, or it may be that other factors, such as the presence of 
cirrhosis per se (Kew and Popper, 1984; Zaman et al, 1985; Johnson and 
Williams, 1987) are linked to HCC development in these patients. 
Unfortunately no tumour tissue from serum HBsAg positive cases was 
available for HBV-DNA probing.
The diversity of patients with respect to age, gender, presence or 
absence and type of cirrhosis, alcohol consumption, and evidence of 
past or present HBV infection, emphasises the complex, multifactorial, 
and probably interactive relationships involved in the aetiology and 
pathogenesis of HCC, particularly in low incidence areas 
(Cook-Mozaffari and van Rensburg, 1984; Kew and Popper, 1984; Zaman et 
al, 1985; Bassendine, 1987).
The median duration of survival from the time of diagnosis of HCC was 
only seven weeks, emphasising the poor prognosis of this condition.
For many reasons, including differing patient characteristics and 
uncertainty over whether survival times are taken from the onset of 
symptoms or the time of diagnosis, an accurate comparison with other 
series is difficult. However, this survival time is considerably 
worse than that seen in previous series of predominantly European 
(Davidson et al, 1974; Melia et al, 1984) and American (Chlebowski et 
al, 1984a) patients and approaches that seen in the rural South 
African black population (Kew and Geddes, 1982) and in a recent large 
series of untreated patients from the Far East (Nagasue et al, 1984). 
The initial poor performance status of the majority of British
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patients would seem the most likely reason for the poor survival 
figures observed, as presenting performance status proved to be a very 
powerful prognostic indicator of survival in this population. The 
presence or absence of cirrhosis also proved to be of prognostic 
importance. This confirms results from predominantly low incidence 
areas (Johnson et al, 1981; Melia et al, 1984) and is in contrast with 
the findings of series from high incidence areas, where cirrhosis has 
little or no effect on the course of the disease (Primak et al, 1975; 
Kew and Geddes, 1982; Nagasue et al, 1984). Age at diagnosis had no 
effect on survival in our HCC population though it did have in other 
series from similar areas (Johnson et al, 1981; Chlebowski et al, 
1984a). This difference probably arises because of the larger 
percentage of cirrhotic patients in the current series compared to the 
others, as it seems likely that the observed improved survival in 
younger patients is explained by the fact that tumours in this age 
group are more likely to arise in a non-cirrhotic liver (Chlebowski et 
al, 1984a). The presence or absence of serum HBsAg did not 
significantly affect the prognosis of British patients, and this is in 
agreement with studies from other regions (Chlebowski et al, 1984a; 
Falkson et al, 1986).
The microscopic features of HCC were in general as described by 
Anthony (1987), the majority being of the trabecular pattern. The 
importance of liver cell dysplasia in the non-malignant liver remains 
controversial. Though a potential pre-malignant lesion (Anthony et 
al, 1973; Ho et al, 1981; Roncalli et al, 1986), its role in this 
regard has been disputed (Cohen et al, 1979; Nakashina et al, 1983; 
Cohen and Berson, 1986) but not resolved. The incidence of liver cell 
dysplasia in the current series was surprisingly higher than that
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reported from other areas (Anthony et al, 1973; Peters, 1976; Cohen et 
al, 1979; Ho et al, 1981; Nakashina et al, 1983), being 53% in those 
patients with biopsies predating the diagnosis of HCC, and rising to 
79% in biopsies taken at the time of HCC diagnosis. No relationship 
between serum HBsAg and liver cell dysplasia could be demonstrated in 
British HCC patients. Prospective controlled studies of the fate of 
patients with liver cell dysplasia and no evidence of HCC development 
are required.
CONCLUSIONS
HCC as seen in the United Kingdom is a disease of male predominance 
with a peak incidence in the sixth decade. It usually arises in a 
cirrhotic liver; approximately 20% of all cases are associated with a 
positive serum HBsAg.
HCC presents late and patients are generally in poor clinical 
condition when diagnosed. The median survival time from diagnosis of 
HCC was only seven weeks. Though effective screening systems to 
detect HCC at an early stage may result in more effective treatment 
for some patients, our results show that almost one half of British 
HCC patients present de novo with HCC and would have escaped 
screening.
The role of liver cell dysplasia in hepatocarcinogenesis merits 
detailed study.
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CHAPTER TWO
THE TREATMENT OF HEPATOCELLULAR CARCINOMA
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This review deals only with the specific treatment of HCC. The relief 
of the symptoms of HCC is not discussed, though this is clearly an 
area of great importance.
PROBLEMS IN ASSESSING HCC TREATMENTS
The accurate evaluation of clinical trials of HCC treatments is 
hindered by many problems. The major drawbacks to individual studies, 
particularly those from areas of low HCC incidence, are usually the 
small size of the study population and the lack of untreated or other 
relevant control groups. The absence of a universally agreed and 
applied definition of what constitutes "response to treatment" and the
pronounced geographic variation in the natural history of HCC both
combine, along with variable patient selection criteria, to render 
between-trial comparisons of specific HCC therapies difficult and 
unwise.
TREATMENT CHOICES IN HCC
Treatment choices may be broadly categorised as shown in Table 2 (i). 
Surgical resection offers the only realistic hope of cure, other 
therapies being palliative. As resection rates are generally low, 
medical (cytotoxic) therapy is the backbone of treatment. Many of the
treatments listed are experimental and require much further
evaluation.
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Table 2 (i)
TREATMENT CHOICES IN HCC.
SURGICAL THERAPY
hepatic resection 
hepatic transplantation
ligation of the hepatic artery or portal vein
RADIATION THERAPY
external irradiation 
"internal" irradiation
CYTOTOXIC CHEMOTHERAPY
single agent 
multiple agent
(intravenous or intra-arterial routes of administration?)
IMMUNOTHERAPY
levamisole 
interferons 
anti-HCC antibodies 
lymphokine-activated killer cells
HORMONAL THERAPY
tamoxifen
cyproterone
progestins
COMBINATION THERAPIES
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THE SURGICAL TREATMENT OF HCC
Surgical resection in HCC is traditionally felt possible only when the 
tumour is confined to one liver lobe, does not involve major vascular 
structures, and arises in a non-cirrhotic liver. Some surgeons 
nowadays will however attempt curative resection in cirrhotic patients 
if liver function is good (Lee et al, 1982; Li et al, 1985; Bismuth et 
al, 1986; Kinami et al, 1986), and in highly selected non-cirrhotic 
patients, specialist hepato-biliary surgeons may achieve apparently 
curative resections even in those with extensive tumours invading 
large blood vessels (S^reide et al, 1985).
Resectability rates vary from one geographic region to another. 
Resectable tumours are found in less than 5% of black Africans with * 
HCC (Harrison et al, 1973; Kew, 1982), whereas in Japanese patients, 
resection rates are substantially higher and appear to be rising, 
probably mainly because HCC is being diagnosed earlier in its natural 
history by screening tests. Between 1968 and 1977 the Japanese Liver 
Cancer Study Group reported a resection rate of 11.9% in 2411 patients 
(Okuda et al, 1980), and for the period 1978 to 1979 this figure had 
risen to 26.6% (Tobe et al, 1982). In these studies patients with 
resectable tumours had one and five year survival rates of 33% and 12% 
respectively, and Okuda et al (1984) have recently reported a one year 
survival rate of 62% for resectable patients, this figure being 
significantly better than that achieved by comparable medically 
treated patients. In China, similar one year survival rates are being 
reported (Li et al, 1985), and resection rates of 60% have been 
reported in patients with sub-clinical HCC detected by screening, with 
five year survival rates of over 70% in resected patients with 
sub-clinical disease (Tang, 1985). In the West, resection rates are
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variably reported. In the older literature, resection rates of less 
than 5% are generally reported (Longmire et al, 1966; Bengmark et al, 
1971; Linder et al, 1974), though in highly selected groups resection 
rates of 23% have been reported (Mabogunje et al, 1975). More 
recently Lim and Bongard (1984) have reported a 25% resection rate in 
86 patients, predominantly Chinese i^ericans, though in a series of 46 
British patients seen at the Royal Free Hospital, London between 1978 
and 1984, the resection rate was only 9% (see Chapter 1). This 
disappointing figure may reflect a referral bias in the population 
studied. Table 2(ii) summarises the results of several recent series 
dealing with hepatic resection in HCC.
In several centres orthotopic liver transplantation has been performed 
on patients considered unsuitable for hepatic resection, either 
because of poor liver function or because of widespread involvement of 
the liver by tumour. Such patients must satisfy the usual criteria of 
suitability for hepatic transplantation (van Thiel et al, 1984) as 
well as have no tumour invasion of major blood vessels and no 
extrahepatic spread of tumour. In those centres where transplantation 
is available, the few results to date suggest that it may have a 
palliative role in HCC treatment (Rolles et al, 1984; Pichlmayer et 
al, 1984). In Rolles' series (1984), 32 of 40 patients with primary 
hepatic tumours survived for greater than 12 months post 
transplantation. Long-term survivors and apparent cures have been 
seen at other centres (Pichlmayer et al, 1984; Krom et al, 1984), and 
Scharschmidt (1984), reporting the combined experience of four 
centres, found a 26% one year survival rate in a group of 139 patients 
transplanted for hepatic malignancy, 62% of whom had HCC. Tumour 
recurrence is a major problem in long-term survivors and in the
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Cambridge/King's College Hospital experience has occurred in 38% of 
their transplanted HCC patients, despite meticulous pre-operative 
screening for metastases (Poison et al, 1987).
Palliative surgery for HCC is rightly unpopular. Occlusion of the 
hepatic artery or portal vein may be achieved without recourse to 
laparotomy (see below).
Emergency surgery may be indicated in those patients who present as an 
acute abdominal catastrophe due to tumour rupture. Resection should 
be undertaken if possible, and if it is not, bleeding may be 
controlled by hepatic artery ligation or by packing the liver. The 
outlook is poor, but occasional long-term survivors are seen (Ong and 
Taw, 1972). If the diagnosis is suspected pre-operatively, hepatic 
angiography may be useful in making the diagnosis and determining 
resectability, and permits trans-catheter arterial embolisation (TAE) 
if desired (see below).
OCCLUSION OF THE HEPATIC ARTERY OR PORTAL VEIN
Whereas non-malignant liver receives a dual blood supply from the 
hepatic artery and portal vein, HCCs are supplied almost exclusively 
by branches from the hepatic artery (Breedis and Young, 1954).
Hepatic artery occlusion may therefore be employed as a treatment for 
HCC, and is probably best achieved non-operatively by TAE performed at 
the time of angiography. This technique allows more selective 
vascular obliteration than is possible at operation and avoids the . 
problems of laparotomy. TAE is hazardous if the portal vein or its
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main branches are thrombosed or if liver function is poor (Yamada et 
al, 1983; Sato et al, 1985a). In these situations portal venous blood 
flow alone cannot maintain satisfactory liver function. Infarction of 
non-neoplastic liver may be seen at autopsy in patients dying 
following TAE in the presence of portal vein thrombosis (Yamada et al,
1983).
Studies of TAE are generally uncontrolled and it remains to be proven 
convincingly that TAE as sole therapy is of therapeutic benefit in 
HCC. The results of three recent large Japanese studies are 
summarised in Table 2 (iii). Revascularisation of tumours is a 
problem, often necessitating repeated TAE or other forms of therapy.
In patients with ruptured HCC, emergency TAE is an effective and 
relatively non-invasive method of controlling haemorrhage (Nouchi et 
al, 1984; Sato et al, 1985b).
Ligation of either the right or left main branch of the portal vein 
has been advocated as a treatment for HCC (Honjo et al, 1975). This 
technique is said to be applicable only to non-cirrhotic patients with 
tumour confined to one liver lobe. Such patients should be suitable 
for hepatic resection, and palliative portal vein occlusion therefore 
seems an inappropriate treatment.
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IRRADIATION
External hepatic irradiation yields disappointing results in HCC 
treatment (Falkson, 1976; Ong and Chan, 1976; Cochrane et al, 1977). 
More recently attempts have been made to irradiate hepatic tumours by 
the administration of radioisotopes bound to anti-tumour antibodies or 
to resin microspheres, in the hope that such techniques will provide 
specific high-dose radiotherapy to the tumour.
131In a poorly designed uncontrolled study, intravenous Iodine bound
to polyvalent anti-ferritin antibodies was reported to be of benefit
in HCC (Order et al, 1985). Unfortunately the co-administration of
cytotoxic agents and external irradiation makes it impossible to
evaluate the contribution of the radiolabelled antibody to the
observed remission rate of 48% of 105 patients. In a preliminary
131communication intra-arterially administered I-anti-AFP, when given 
in conjunction with cytotoxic chemotherapy, has been reported to 
confer some survival advantage over chemotherapy treatment alone (Lin 
et al, 1983). This result awaits confirmation.
90Microspheres containing Yttrium have been administered via 
the hepatic artery to HCC patients (Ariel and Pack, 1970; Grady,
1978). The microspheres become trapped in the tumour vasculature and 
beta radiation is emitted to a depth of approximately 8 mm. Very few 
HCC patients have been treated and no conclusion can be reached about 
the efficacy of such therapy.
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CYTOTOXIC CHEMOTHERAPY
The majority of clinical trials of cytotoxic chemotherapy in HCC are 
small, uncontrolled, and unhelpful. Drugs which show promise in phase 
II studies require further' evaluation in properly conducted phase III 
trials before their role in HCC therapy can be defined, and such 
studies are generally lacking. The evaluation of chemotherapy studies 
would be aided by the universal adoption of a standard set of response 
criteria, perhaps based on those described by Miller et al (1981).
Single Agent Therapy
The antimetabolite 5-fluorouracil (5-FU) was the first cytotoxic to be 
extensively investigated as a single agent therapy in HCC. Results 
were generally poor and the drug is now rarely used. Kennedy et al 
(1977) reported some benefit from oral 5-FU (six of 12 patients 
responding) but two other studies (Link et al, 1977; Falkson et al, 
1978), the largest of which involved 48 patients, found no responses 
to oral therapy. Intravenous 5-FU is likewise disappointing (Gailani 
et al, 1972; Al-Sarraf et al, 1974; Link et al, 1977), though 
occasional long-term responders may be seen (Davis et al, 1974).
Doxorubicin (Adriamycin) is perhaps the most widely used single agent
therapy for inoperable HCC at present. The drug is usually given
intravenously every 21 days. A reduced dosage is usually given if
jaundice is present, though recent work has suggested that this may be
inappropriate and lead to the administration of sub-therapeutic doses
(Johnson et al, 1986). Toxicity is significant and side-effects
include nausea and vomiting, mucositis, alopecia, bone marrow
depression, and dose-related cardiotoxicity. Fear of cardiotoxicity
2
usually limits the total cumulative dose administered to 550 mg/m .
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The results of studies with doxorubicin are summarised in Table 2 
(iv). The initial encouraging results of Olwney et al (1975) have not 
been observed in subsequent studies (Vogel et al, 1977; Ihde et al, 
1977; Johnson et al, 1978c; Olweny et al, 1980; Falkson et al, 1984a; 
Chlebowski et al, 1984b; Choi et al, 1984; Sciarrino et al, 1985), and 
response rates are usually less than 20%-30%. Those responding 
generally do so by the end of the third cycle, and lack of response at 
this time indicates a need to change therapy.
Anthracyclines which are less toxic than doxorubicin are now 
available. Mitozantrone is discussed in detail in Chapter 3. Phase 
II studies so far performed with this agent have produced similar 
response rates to those observed with doxorubicin but with excellent 
tolerability (Falkson et al, 1984b; Dunk et al, 1985). 
4'epidoxorubicin, a stereoisomer of doxorubicin with reduced 
cardiotoxicity, has been examined in a small number of HCC patients 
(Hochster et al, 1985; Shiu et al, 1986). Response rates were 
disappointing and complications such as nausea and alopecia appeared 
more common than in the studies with mitozantrone.
A variety of other drugs have been used as single agent therapy for 
HCC. All have proved disappointing and the results of the best 
conducted of the many studies are summarised in Table 2 (v).
Treatment with interferons is discussed in detail below.
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Multiple Agent Therapy
Cytotoxic drug combinations have little to offer over single agent 
therapy with doxorubicin. Any marginal benefit in terms of response 
is invariably offset by unacceptable toxicity. The combination of a 
variety of agents with doxorubicin, including bleomycin (Ravry et al,
1984), 5-FU (Baker et al, 1977), methyl-CCNU (Chlebowski et al, 1981), 
methyl-CCNU plus 5-FU (Falkson et al, 1984a), dichloromethotrexate, 
5-asacytidine, rezoxane and cyclophosphamide (all Olweny et al, 1980), 
have all proved disappointing.
Intra-arterial Chemotherapy
There are no satisfactory controlled trials comparing the 
intra-arterial and intravenous routes of drug administration. The 
uncontrolled and generally unimpressive results of intra-arterial 
chemotherapy for HCC have recently been reviewed (Opfell and Bowen,
1985). Any benefit of intra-arterial over intraveous therapy in terms 
of response is probably outweighed by the technical problems of 
intra-arterial treatment (Bottino, .1985), though these are becoming 
less common as new infusion devices are developed. The recent 
suggestion that intra-arterial doxorubicin may precipitate hepatic 
failure in HCC patients with cirrhosis is worrying and requires 
clarification (Tommasini et al, 1986).
The oily X-ray contrast medium Lipiodol is selectively retained in 
tumour tissue for many months after intra-arterial administration, and 
CT scanning seven-10 days after intra-arterial Lipiodol has been 
suggested as superior to either CT scanning or angiography alone in 
detecting the true extent of HCC spread within the liver (Yumoto et
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al, 1985). Lipophilic cytotoxic drugs such as styrene maleic acid 
neocarzinostatin (SMANCS) have been solubilised in Lipiodol and 
administered intra-arterially to HCC patients in the hope of prolonged 
retention of cytotoxic activity within the tumour (Tashiro and Maeda, 
1985). An uncontrolled Japanese study of 94 patients, in which 
response criteria were not accurately defined, has yielded encouraging 
results which require confirmation in a properly controlled and 
blinded trial (Tashiro and Maeda, 1985). Hydrophilic drugs such as 
doxorubicin may be successfully admixed with Lipiodol in the presence 
of the X-ray contrast material Urografin, which is water soluble but 
of the same specific gravity as Lipiodol (Kanematsu et al, 1984). The 
results of an uncontrolled study of this form of therapy are of 
encouragement (Kanematsu et al, 1984). The use of "lipiodolised" 
cytotoxic drug therapy merits full evaluation in controlled studies 
with "conventional" intravenous and intra-arterial treatment.
IMMUNOTHERAPY
Levamisole, a stimulator of cell-mediated immunity, did not improve 
the survival of Oriental patients when given after recovery from 
operative hepatic arterial obliteration (Plengvanit et al, 1986).
Interferons possess a wide range of immunomodulatory and direct 
antiproliferative properties (Gresser and Tovey, 1978; Borden and 
Ball, 1981; Steihm et al, 1982), and because of these, they are now 
being extensively examined as potential therapies for a variety of 
malignancies. Three studies in small numbers of HCC patients have so 
far been reported. Sachs et al (1985) found recombinant leucocyte . 
interferon to be of no benefit to 16 black South African patients, and
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toxicity was such that in 10 patients the drug had to be either
discontinued or the dosage reduced. A lower dose of a leucocyte
interferon preparation was found by Nair et al (1985) to be safe and
capable of immune stimulation, though no responses to therapy were
noted in their study of only five patients. Recombinant gamma
6 2interferon in a dose of 2.7 x 10 IU/m produced no responses to 
therapy after four weeks treatment and toxicity was such that the 
study was discontinued after recruitment of only seven patients 
(Forbes et al, 1985). These trials allow one to conclude only that 
interferons possess significant toxicity when given to HCC patients in 
doses that would usually be tolerable to subjects without severe 
parenchymal liver disease. The numbers of patients studied are too 
small to allow meaningful assessment of anti-tumour activity. Further 
studies are needed to determine the toxicity and efficacy of low dose 
intereron therapy, and the possible synergy which exists between 
interferons and the anthracyclines (Green et al, 1985) may be worthy 
of exploration in HCC.
Immunotherapy with antibodies directed against HCC-associated antigens
is an exciting prospect for future treatment, and may enable the
selective targeting of drugs, isotopes or potent cellular toxins to
tumour cells. Clinical trials in a variety of different malignancies
are now under way and these have recently been reviewed by Morgan and
Foon (1986) and Baldwin and Byers (1986). The uncontrolled studies so
far performed in HCC patients (Liu et al, 1983; Order et al, 1985),
131both involving I- labelled polyvalent antibodies have already been 
discussed. As yet there are no reported studies of HCC immunotherapy 
with monoclonal antibodies to non-secreted cell surface antigens, and
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no reports of HCC therapy with antibodies conjugated with either 
cytotoxic drugs or toxins.
Recently, lymphokine activated killer (LAK) cells have been suggested 
as a potential form of passive ("adoptive") immunotherapy in cancer 
patients. Preliminary studies in which LAK cells and interleukin-2 
(IL-2) have been infused together demonstrated remission in 11 of 25 
patients with a variety of advanced malignancies (Rosenberg et al,
1985). In vitro experiments in a small number of HCC patients have 
shown that their IL-2 stimulated killer cells have enhanced 
cytotoxicity against fresh autologous and allogeneic tumour cell 
suspensions and established HCC cell lines (Hsieh et al, 1987). So 
far only one HCC patient has received intra-arterial treatment with 
autologous LAK cells (Okuno et al, 1986). A transient fall in AFP was 
noted, with levels soon rising to pre-treatment values again. IL-2 
was not infused concurrently.
HORMONAL THERAPY
The rationale behind the suggestion that HCC may be a hormonally 
dependent tumour is discussed in Chapter 5. Two small uncontrolled 
studies have shown modest objective responses of HCC to hormonal 
manipulation with cyproterone acetate (Forbes and Williams, 1987) and 
a combination of tamoxifen and norethisterone (Trinchet et al, 1985). 
There is also anecdotal evidence of HCC regression in response to 
progestogen therapy (Friedman et al, 1982). Clinical trials with 
tamoxifen are currently underway in South Africa, though no benefit 
has so far been seen with this agent when given alone (Paliard et al,
1984) or in combination with cytotoxic drugs (Melia et al, in press).
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COMBINATION THERAPIES
No satisfactory controlled clinical trials of combinations of 
different modalities in HCC treatment exist. As any advantage of 
combination therapy over treatment with one single modality is likely 
to be small, large numbers of patients are required for such trials, 
in order that small treatment differences may be detected with 
confidence.
<
CONCLUSIONS
HCC remains a disease of grave prognosis, mainly because the tumour 
usually presents late in its natural history, when operation is not 
possible. The results of operation in early disease are of some 
encouragement and every effort should be made to regularly screen the 
cirrhotic population at risk for HCC development.
The outlook for inoperable patients remains gloomy though exciting new 
treatment modalities exist which require extensive evaluation. An 
anthracycline given as single agent intravenous therapy is probably 
the current treatment of choice for these patients, though only 
20%-30% will show a response.
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CHAPTER THREE
MITOZANTRONE AS SINGLE AGENT THERAPY IN HEPATOCELLULAR CARCINOMA
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ABSTRACT
Thirty-five patients with HCC have been treated with the 
Anthracenedione mitozantrone (dihydroxy-anthracenedione 
dihydrochloride). One complete and five partial responses to therapy 
were seen, and in a further four patients tumour size remained static 
for lengths of time ranging from 13 to 42 weeks.
Therapy was well tolerated. Bone marrow suppression was dose-limiting 
but easily managed by dose reduction. Other acute toxicity was rare, 
vomiting and hair loss being reported only once each. Cardiac 
'events' occurred in five patients, three of whom had received high 
total cumulative doses of mitozantrone.
It is concluded that mitozantrone is of clinical benefit in some 
patients with HCC and that its usage is compatible with a good quality 
of survival. Its cardiotoxic potential requires further evaluation.
INTRODUCTION
As discussed in Chapter 2, cytotoxic chemotherapy is currently the 
mainstay of treatment in HCC, though results are generally 
disappointing. Doxorubicin (Adriamycin) is usually regarded as the 
drug of choice, though response rates are generally less than 20%-30% 
(Vogel et al, 1977; Ihde et al, 1977; Johnson et al, 1978c; Olweny et 
al, 1980; Falkson et al 1984a; Chlebowski et al, 1984b; Choi et al, 
1984; Sciarrino et al, 1985). Doxorubicin is toxic and frequently 
causes nausea, vomiting, alopecia and mucositis. A serious
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disadvantage is dose-dependent cardiotoxi H  tv (T.pfrpk pt* al . 1Q73;
patients who show a useful clinical response. New chemotherapeutic 
agents are urgently needed which are both less toxic and more 
efficacious in HCC than doxorubicin.
Mitozantrone (Figure 3(i)) is an anthracenedione structurally related 
to doxorubicin but without the amino-sugar moiety postulated by 
Adamson (1974) to be responsible for doxorubicin cardiotoxicity. In 
animal model systems mitozantrone has shown anti-tumour activity 
comparable and often superior to doxorubicin, in association with 
minimal or absent cardiotoxicity (Fujimoto and Ogawa, 1982; Henderson 
et al, 1982; Schabel et al, 1983). Phase I studies have suggested 
that mitozantrone is well tolerated and has a low incidence of serious 
side-effects (Von Hoff et al, 1980; Alberts, 1980), and early phase II 
studies suggest that mitozantrone may be of benefit in breast cancer, 
acute leukaemia and the malignant lymphomas (Prentice et al, 1983; 
Coltman et al, 1983; Stuart-Harris et al, 1984). In this chapter the 
findings of a multicentre phase II study of mitozantrone as single 
agent therapy in inoperable HCC are reported.
PATIENTS AND METHODS
Patients were considered eligible for study if they had histologically 
proven HCC or a serum AFP > 500 IU/ml in conjunction with a hepatic 
arteriogram showing hypervascular tumour circulation. Patients were 
excluded from the study if they had received any prior form of therapy 
for HCC, if the tumour was considered resectable, or if they were of 
WHO performance grade 4 (World Health Organisation, 1979), i.e.
Unverferth et al, 1982) which may limit
56
HO 0 NCH2 CH2NCH2 CH20H 
H H
Figure 3 (i)
CHEMICAL STRUCTURE OF MITOZANTRONE.
completely disabled and totally confined to bed or chair. Between 
January 1982 and January 1984, 35 suitable patients were enrolled for 
study. A further five subjects who had previously had some other form 
of therapy for HCC were subsequently given mitozantrone as single 
agent therapy. They have been considered only for toxicity analysis.
The characteristics of the 35 patients considered suitable for study 
are shown in Table 3(i). There were 29 men and six women. Ages 
ranged from 10 years to 76 years with a mean age of 56.8 years (median 
57 years). Twenty-one patients were non-British. Thirty patients had 
disease confined to the liver alone and five patients had metastatic 
HCC. Three patients (numbers 2, 9 and 14) had multiple pulmonary 
metastases, one patient (number 4) had bony metastases and one patient 
(number 7) had HCC deposits in supraclavicular lymph nodes. HBsAg was 
detected in the serum by radioimmunoassay (Ausria, Abbot Laboratories, 
UK) in eight patients. Cirrhosis was present in 24 patients and 
absent in seven, and the state of the underlying non-malignant liver 
in the remaining four patients was not known. The diagnosis of HCC 
was confirmed histologically in 25 subjects and in the remainder was 
based on a serum AFP of > 500 IU/ml (RIA-gnost AFP, Hoescht 
Laboratories, UK) and a characteristic angiogram. Serum AFP was < 10 
IU/ml in five subjects, between 10 and 100 IU/ml in three, between 101 
and 500 IU/ml in four and >500 IU/ml in the remaining 23 subjects.
Prior to treatment all patients were fully examined and the size of 
the enlarged liver was recorded by measuring in the mid-clavicular 
line the distance between the right costal margin and the liver edge 
at the end of quiet inspiration. Liver function tests, full blood 
count and serum AFP were measured immediately before treatment and an
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Table 3 (i)
PRETREATMENT PATIENT CHARACTERISTICS AND RESPONSES TO THERAPY.
Patient
No
Sex/
Age
(yr) Race HBsAg
AFP
(IU/ml) Cirrhosis
WHO
Performance
Grade Response
Duration of
Response
(weeks)
1 M/52 Greek _ 4000 _ 1 PD _
2 F/53 British - <10 - 2 NE -
3 M/52 Saudi + 360000 - 3 PD -
4 F/55 British - 11520 - 0 PD -
5 M/70 Saudi - 600 NK 2 NE -
6 M/35 Saudi + 13 - 0 PD -
7 M/21 British - <10 - 0 PD -
8 M/55 Saudi - 48800 NK 1 PD -
' 9 M/52 Greek - 6900 + 1 NE -
10 M/71 British - 26400 + 1 NE -
11 M/63 British - 133 + 0 PD -
12 F/63 British - <10 - 0 PD -
13 M/75 Omani + 147 + 3 PD -
14 M/52 British - 91200 + 1 NE -
15 M/57 Quatari - 13900 + 3 NE -
16 M/66 British + 13100 + 3 NE -
17 M/46 Nigerian - 4000 + 1 PD -
18 M/59 British - 16000 + 3 NE -
19 M/59 West Indian - 125 + 3 NE -
20 M/56 Zambian + 23500 NK 2 NE -
21 M/56 Saudi + 58 - 2 NE -
22 M/76 British - 43800 + 2 NE -
23 M/73 British - 6200 + 1 PD -
24 M/69 Saudi - 7330 + 1 NE -
25 M/66 French - 8730 + 1 PD -
26 M/50 Italian - 37200 + 1 CR 13
27 M/69 British - 1769 + 1 PR 3
28 M/65 Omani - 3041 + 2 PR 6
29 M/53 Italian - 1662 + 1 PR 6
30 M/10 Israeli - 37700 - 0 PR 17
31 M/52 Italian - 62 + 1 PR 29
32 F/62 British - <10 - 0 NC 24
33 F/61 Yugoslavian - 2100 + 1 NC 29
34 F/76 British - <10 NK 1 NC 42
35 M/38 Omani + 318 + 2 NC 13
Abbreviations: NK “ Not Known; NE ** Not Evaluable; PD - Progressive Disease;
CR ~ Complete Response; PR = Partial Response; NC - No Change
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electrocardiogram (ECG) performed. Pretreatment tumour size was also 
assessed by computerised tomography of the liver or by ultrasound
2
examination. Mitozantrone was diluted in 5% dextrose and 12 mg/m was
infused intravenously over 10-30 minutes every 21 days. The dosage
2
was increased or decreased by increments of 2 mg/m depending on 
toxicity and response. In mid-cycle (between days 10 and 14) the full 
blood count was measured and immediately prior to each subsequent 
cycle of therapy this was repeated, as were the liver function tests 
and the serum AFP. The patients' WHO performance grade and adverse 
events following each cycle were recorded using a standard 
questionnaire with toxicity for each body system graded 0-4 according 
to the WHO classification (World Health Organisaton, 1979). Tumour 
size was assessed clinically during every cycle and CT or ultrasound 
examination were repeated after every two to three cycles.
Response criteria were defined using a modification of internationally 
accepted criteria (Miller et al, 1981). A complete response (CR) was 
defined as complete disappearance of all known tumour deposits and a 
decrease in the serum AFP to less than 20 IU/ml in those patients in 
whom this parameter was initially elevated. A partial response (PR) 
required a reduction in the total size of all measurable lesions of at 
least 50%, or a greater than 50% fall in serum AFP concentration.
Where the liver was diffusely replaced by tumour, response was 
assessed using clinical measures of liver size and a PR required at 
least a 50% reduction in hepatomegaly as measured by distance below 
the right costal margin in the mid-clavicular line. A response was 
considered to have occurred if the required change occurred in one . 
parameter, provided there was no contradictory change in the other
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parameter. "No change" (NC) was defined as a change in total tumour 
size or AFP concentration which amounted to less than a 50% reduction 
or a 25% increase in either parameter. Progressive disease (PD) was 
defined as the appearance of any new lesion or a greater than 25% 
increase in either tumour size or serum AFP concentration. Patients 
were considered non-evaluable for response analysis if they did not 
complete six weeks of therapy or if there were insufficient follow-up 
data, or if a major protocol violation affecting treatment scheduling 
occurred.
RESULTS
Responses to treatment
Of the 35 patients eligible for study, 22 were evaluable for response 
and 13 were not. The reasons for non-evaluability are listed in Table 
3 (ii). The main reason was early death due to malignancy, defined as 
death attributable to malignancy occurring within six weeks of 
starting treatment. A complete response was seen in one patient (4.5% 
of those evaluable) and lasted 13 weeks. There were five partial 
responses (22.7%) of mean duration 12 weeks (range 3-27 weeks). Four 
patients (18.2%) remained in the "no change" category for a mean 
duration of 27 weeks (range 13-42 weeks) and the remaining 12 
evaluable patients (54.6%) showed evidence of progressive disease.
Patients who showed a complete or partial response to therapy 
responded within the first six weeks of treatment. In those patients 
in whom it was raised, serum AFP fell rapidly and CT scan or 
ultrasound showed a > 50% reduction in tumour size. In all patients 
responding, general well-being, measured in terms of WHO performance
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Table 3 (ii)
NON-EVALUABLE PATIENTS: REASONS.
Patient numbers Reasons
2, 24 Protocol violation
9 Inadequate data
5, 10, 14-16, 18-22 Early death due to malignancy*
* death < 6 weeks from start of treatment
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grade, either remained static (four patients) or improved (two 
patients). Patients in the "no change" category showed static (two 
patients) or improved (two patients) performance grade, and tumour 
size and serum AFP concentration remained around pretreatment values. 
In contrast, patients with progressive disease refractory to 
mitozantrone showed a deterioration in performance grade and a 
steadily increasing tumour size was noted by CT scan or ultrasound 
examination.
Mitozantrone therapy was continued in all groups of patients until 
they showed evidence of progressive disease (a > 25% increase in the 
lowest recorded tumour size or AFP concentration). Therapy was then 
changed to a variety of other agents and all patients were followed up 
until death.
The median duration of survival of patients with progressive disease 
was significantly shorter than that for those who showed "no change" 
or some form of response to treatment (17 weeks vs 82 weeks, p<0.05,
log-rank test). The median duration of survival of the 22 evaluated
patients was 53 weeks, and that for the 35 patients originally
eligible for study was 16 weeks (Figure 3 (ii)).
Toxicity
Toxicity analysis was performed on data collected from the 35 patients 
entered into the Phase II study and from a further five patients who 
had previously had other forms of treatment for HCC.
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Figure 3 (ii)
KAPLAN-MEIER SURVIVAL CURVE OF ALL PATIENTS (n = 35) ELIGIBLE FOR 
STUDY.
Changes in total white cell and platelet counts are illustrated in
Figure 3 (iii). A total white cell count (WCC) of less than 1.0 x 
9
10 /I was noted on four occasions and two patients developed 
infections during treatment. One patient developed septicaemia which 
responded to appropriate treatment during a cycle associated with a
9
nadir WCC of 1.1 x 10 /I and another developed a urinary infection
9
associated with renal calculi and a nadir WCC of 0.4 x 10 /l. A
Q
platelet count of less than 40 x 10 /I occurred on four occasions and 
one patient with renal calculi (the same patient as that with the 
urinary infection) developed haematuria associated with a nadir
9
platelet count of 66 x 10/1.
Cardiac toxicity was detected clinically and by ECG, which was 
performed after every second or third cycle. In addition, six 
patients had radionuclide ventriculography prior to mitozantrone 
therapy, which was then repeated after every third cycle of therapy. 
This is an accepted non-invasive technique for the assessment of left 
ventricular function, and testing was performed both at rest and on 
stress (Alexander et al, 1979). Cardiac events were noted in five of 
40 patients (12.5%) and are listed in Table 3 (iii). One patient with 
pre-existing left bundle branch block developed atrial fibrillation 24 
hours after the first injection of mitozantrone. This responded to 
digitalis treatment and did not recur on subsequent injections. A 
further patient, who had been heavily pre-treated with doxorubicin and 
who had developed incomplete right bundle branch block while on this 
drug, developed complete heart block 48 hours after the first 
injection of mitozantrone. The patient died six days later, still in 
complete heart block. Cardiac events occurred in three other
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Figure 3 (iii)
PRETREATMENT AND NADIR WHITE CELL AND PLATELET COUNTS DURING 
MITOZANTRONE THERAPY.
Ta
bl
e 
3 
(i
ii
)
H
S3Cd
s
H
< 1
WP3
H
W
Z
O
P i
H
§Csl
O
H
OS3M
PiCO
Q
cn
H53W>
W
CJ
<J
M
O
Pi
c
CJ
CJ 4-1
cs
•H
<N CM
co co
•H
•H
co
m
m
m
oo
•H
U
CO
CO
Mo
oI—IJO • 
cd
jd  -H  
CJ 'C
d *■* 
d  cd u 0 jo to 
X  <u o
r-l Cd •73 J_)
cd iH
jo cd
•Hu u
-d +j
bo cd
•H
d  t—I
cd
I! S
CO
PQ tO 
PQ X
PP
Pi
CJ
O H 
JO CU
rd
CJ
d  d  
cd cd
d  iH
jo d 
o
CD *H
r—I d
TO 4-1
d  d  
d  cd 2^ >
4-) 4J
M-i Id
a) cd
1 1
pa >  
pq hJ 
pa
hJ
cn
d
o
•H
4-4
cd
•H
>
<U
d
JO
5
64
patients, none of whom had any risk factors for cardiac disease. All 
had received high total cumulative doses of mitozantrone (Table 3 
(iii)). Mitozantrone was discontinued and cardiac function did not 
deteriorate further.
Other treatment-related side-effects are listed in Table 3 (iv). The 
drug was generally well tolerated. Only one patient experienced 
vomiting during mitozantrone treatment and this was limited to the day 
of injection. Hair loss, an almost universal problem with 
doxorubicin, was reported by only one patient and was not cosmetically 
troublesome. The most frequent side-effect was WHO grade 1 nausea 
whch was experienced by 27% of patients.
DISCUSSION
As discussed in Chapter 2, doxorubicin is widely accepted as the best 
single agent form of therapy currently available for inoperable HCC. 
Response rates however are poor, being generally less than 20-30% (see 
Table 2 (iv), p47), and the combination of other cytotoxic agents with 
doxorubicin has so far either failed to improve these depressing 
results (Baker et al, 1977; Chlebowski et al, 1981), or has marginally 
done so at the expense of severe drug-related toxicity (Falkson et al, 
1984a).
In this study, one complete and five partial responses were noted in 
22 evaluable patients, an overall response rate of 27.3%. In 
addition, four further patients remained in the "no change" category 
for clinically significant lengths of time ranging from 13-42 weeks.
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Thus we feel that mitozantrone was of clinical benefit in 45.4% of our 
evaluable patients (28.6% of the 35 patients originally entered). The 
only other phase II study of mitozantrone in HCC (Falkson et al,
1984b) has been performed in a small number of predominantly black 
patients from South Africa and a response rate of only two from 17 
patients (11.7%) was noted, a figure similar to that observed in many 
of the studies with doxorubicin. Clearly a phase III study comparing 
mitozantrone and doxorubicin in HCC is indicated.
Mitozantrone produced a statistically significant increase in survival 
in those patients who had a response to treatment or remained in the 
"no change" category, when compared to those patients with progressive 
disease refractory to mitozantrone. It should be noted however that 
the median duration of survival of the whole group of patients 
originally considered eligible for study was only 16 weeks. This 
disappointing figure is accounted for by the large number of early 
deaths due to malignancy seen in those patients of WHO performance 
grades 2 and 3 (eight of the 10 early deaths due to malignancy seen), 
and our experience would suggest that these patients should probably 
not be included in phase II studies of cytotoxic agents in HCC, as 
they are unlikely to survive long enough to be evaluable for response.
Mitozantrone treatment was given on an out-patient basis once every 21 
days. A standard dosage regime was used in all patients irrespective 
of liver function, and was well tolerated.
Myelosuppression was rarely a clinical problem and could easily be 
managed by dosage adjustment. There was no evidence of significant 
cumulative myelosuppression with continued mitozantrone usage.
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Doxorubicin causes both acute and chronic cardiac toxicity (Lefrak et
al, 1972; Unverferth et al, 1982). The latter dose-dependent
cardiotoxicity may lead to congestive cardiac failure and death and
2
becomes increasingly common at cumulative doses of over 540 mg/m .
Mitozantrone, in animal model systems, has shown little or no
cardiotoxic potential (Henderson et al, 1982; Fujimoto and Ogawa,
1982; Schabel et al, 1983). In this study five cardiac events were
noted. Two subjects developed serious cardiac arrythmias within 48
hours of their first injection of mitozantrone. Both had pre-existing
ECG abnormalities and one had been heavily pre-treated with
doxorubicin. The other three cardiac events occurred at high
cumulative doses of mitozantrone, in subjects with no pre-existing
cardiac disease. Mitozantrone therapy was withdrawn and no further
deterioration in cardiac function was noted in these patients.
Cardiotoxicity has been noted during mitozantrone treatment by several
other investigators (Schell et al, 1982; Unverferth et al, 1983) and
prior treatment with anthracyclines seems to increase the risk of its
development. Until the cardiotoxicity of mitozantrone is fully
evaluated it is currently recommended that treatment proceed with
caution above cumulative dose levels of 100-120 mg/m in anthracycline
2
pre-treated patients and above 140-160 mg/m in non-pretreated 
patients (Crossley, 1983).
Other side-effects were uncommon and mild, and the quality of survival 
of responding patients was excellent. Only one patient suffered 
vomiting and only one patient reported hair loss during treatment.
This was of WHO grade 1 severity only.
68
We conclude that mitozantrone appears to have activity in HCC, 
probably at least equal to that seen with other cytotoxic agents, and 
that its usage is associated with a low incidence of serious 
side-effects, though its potential cardiotoxicity requires further 
evaluation. It should be noted however, that the median duration of 
survival of our 35 patients was only 16 weeks from the start of 
treatment. New methods are therefore needed for diagnosing HCC at an 
early stage, when surgical cure might be possible, and novel modes of 
treatment such as interferon therapy (Chapters 5 and 6), hormonal 
manipulation (Chapter 7), and immunotherapy with anti-HCC monoclonal 
antibodies (Chapter 8), should be urgently evaluated.
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CHAPTER FOUR
HUMAN HEPATOCELLULAR CARCINOMA CELL LINES AND THE PRODUCTION OF TUMOUR 
XENOGRAFTS IN ATHYMIC (NUDE) MICE: BACKGROUND AND METHODOLOGY
70
INTRODUCTION
New and more efficacious cytotoxic drugs are urgently required for HCC 
treatment, and novel modes of treatment such as interferon therapy 
(Chapters 5 and 6), hormonal manipulation (Chapter 7) and 
immunotherapy with anti-HCC monoclonal antibodies (Chapter 8) require 
evaluation. Many of the experiments detailed in subsequent chapters 
have utilised human HCC tumour xenografts growing in athymic (nude) 
mice as an animal model for the preliminary testing of the in vivo 
response of human HCC to such therapies and as a ready source of 
tumour tissue for in vitro study. This chapter briefly describes the 
characteristics of the athymic mouse and its role in the screening of 
new anti-cancer therapies, and also details the materials and methods 
used for the in vitro culture of human HCC cell lines, the housing of 
athymic mice, and the production of HCC tumour xenografts.
ATHYMIC (NUDE) MICE; THEIR HISTORY AND ROLE IN CANCER RESEARCH 
Flanagan (1961) was the first to describe the nude mouse mutant, so 
called because of the almost total absence of body hair in 
homozygotes. He recognised the autosomal recessive mode of 
inheritance of the trait and that when kept under conventional 
conditions, these animals had a short life span. It was Pantelouris 
(1968), working at Strathclyde University, who first reported thymic 
dysgenesis in nude mice, and shortly thereafter, in the light of the 
then recent discovery of thymus-dependent cell-mediated immunity 
(Miller, 1961), the first reports of the transplantation of human 
tumours in athymic mice and the production in these immunologically 
incompetent animals of tumour xenografts derived from tumour cell 
lines were published (Rygaard and Povlsen, 1969; Giovanella et al,
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1972). Since that time the immunological status of athymic mice has 
been extensively investigated (Kindred, 1978; Herberman, 1978; 
Giovanella and Fogh, 1985), many tumours have been grown as xenografts 
(Sharkey et al, 1978), and the animal is now widely used as an in vivo 
test system for screening the cytotoxic activity of new anti-cancer 
therapies. The advantages of the athymic mouse over other in vivo 
systems which may be used for this purpose have recently been reviewed 
(Giovanella and Fogh, 1985), as have the limitations of the nude mouse 
tumour xenograft model when used to screen anti-cancer drug activity 
(Sharkey and Fogh, 1984; Giovanella and Fogh, 1985). An obvious 
disadvantage, as discussed in more detail in Chapter 5, is the 
inability to accurately assess the effects on tumour growth of agents 
which act partly or wholly on the host immune system.
Bassendine et al (1980), using the PLC/PRF/5 cell line (see below), 
described the production of HCC xenografts in athymic mice. In these 
studies the morphology of xenografted tumours was similar to that of a 
well differentiated HCC, and xenografts produced HBsAg and AFP in 
amounts readily detected in mouse serum. Subsequent studies 
(Bassendine et al, 1983) determined the growth charactersitics of 
PLC/PRF/5-derived xenografts and revealed a strong positive 
correlation between tumour xenograft mass and mouse serum AFP 
concentration. The ease with which the PLC/PRF/5 cell line can be 
xenografted, and the ability to utilise tumour size, serum AFP 
concentration, and mouse survival as indicators of reponse to therapy, 
make the athymic mouse-tumour xenograft model the best currently 
available in vivo test system for the rapid preliminary evaluation of 
potential new anti-HCC therapies.
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HCC CELL LINES
In almost all of the experiments to be detailed subsequently the 
PLC/PRF/5 cell line was chosen as the human HCC cell line for study. 
This cell line was established in 1973 and is derived from the tumour 
of a 24 year old Mozambican male whose serum was positive for both 
HBsAg and AFP (Alexander et al, 1976). PLC/PRF/5 cells contain 
genomically integrated HBV-DNA sequences and secrete HBsAg but no 
other HBV proteins (Alexander et al, 1976; Bassendine et al, 1980; 
Chakraborty et al, 1980). AFP, though not detectable when PLC/PRF/5 
cells are grown in tissue culture, is readily detectable when cells 
are grown as xenografts (Bassendine et al, 1980).
The SK-Hep-1 and Mahlavu cell lines, which are utilised in Chapter 7, 
are poorly described in the literature. The SK-Hep-1 cell line is 
derived from the tumour of a male patient (Fogh and Trempe, 1975) and 
does not produce HBsAg (Shouval et al, 1983). The sex of the patient 
from whom the Mahlavu cell line is derived is not stated in the 
literature (Prozesky et al, 1973). This cell line contains integrated 
HBV-DNA sequences in low copy number and produces HBsAg only when 
stimulated by dexamethasone (Oefinger et al, 1981).
CELL CULTURE CONDITIONS AND THE PRODUCTION OF HCC TUMOUR XENOGRAFTS 
PLC/PRF/5 cells were grown as monolayers in modified Eagle's medium 
(MEM) with Earle's salts (Gibco Ltd, Paisley, UK), and the SK-Hep-1 
and Mahlavu cell lines were both grown as monolayers in RPMI 1640 
medium (Flow Laboratories, Irvine, UK). Both media were supplemented 
with 10% v/v foetal calf serum, L-glutamine and antibiotics (Gibco . 
Ltd, Paisley, UK). Cells were grown at 37°C in a: humidified
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atmosphere of 95% air and 5% CC^, and media were changed twice weekly. 
Cells were harvested by mild trypsinisation and gentle agitation in 
trypsin - EDTA.
All animal studies utilised sexually mature male athymic (nu/nu) mice 
of either BALB/c or CBA strain. Each experiment involved mice of only 
one strain. Athymic mice were housed in sterile filter cages in a 
room separate from other experimental animals. Laboratory feed was 
irradiated and drinking water was acidified to minimise the risk of 
pseudomonas infection. All handling was performed using strict 
aseptic techniques.
Tumour xenografts were produced as described by Bassendine et al 
(1980). Mice received sub-lethal whole body irradiation of 450 rads. 
Forty-eight hours later 10 viable tumour cells, as determined by 
trypan blue dye exclusion, were injected subcutaneously into the loose 
tissues over the neck region. Tumour xenografts usually appeared 
within three to six weeks of injection. Xenografts of each of the 
three HCC cell lines grew as localised, well circumscribed, nodular 
tumours (Figure 4(i)). No evidence of local invasion of deeper 
structures or of distant metastases was found at post-mortem, which 
was performed on almost all animals studied.
Only PLC/PRF/5-derived xenografts, whose growth characteristics in 
athymic mice have been detailed previously (Bassendine et al, 1983), 
were used in experiments studying tumour growth in vivo. Tumour 
growth was assessed both by measuring the two largest tumour diameters 
at right angles to each other with precision calipers and obtaining. 
the product, the tumour base area, and by measuring mouse serum AFP
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Figure 4 (i)
ATHYMIC (NUDE) MOUSE WITH A TUMOUR XENOGRAFT DERIVED FROM THE 
PLC/PRF/5 CELL LINE.
concentration by radioimmunoassay (RIA-gnost AFP, Hoechst 
Laboratories, UK). Animals with PLC/PRF/5-derived tumour xenografts 
survive approximately four to eight weeks from the time of the tumour 
development (Bassendine et al, 1980).
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CHAPTER FIVE
THE EFFECTS OF HUMAN LYMPHOBLASTOID INTERFERON ON THE GROWTH OF THE 
HUMAN HEPATOCELLULAR CARCINOMA CELL LINE PLC/PRF/5: STUDIES IN VITRO
AND IN ATHYMIC MICE WITH PLC/PRF/5-DERIVED TUMOUR XENOGRAFTS
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ABSTRACT
The growth inhibiting effects of human lymphoblastoid interferon 
(Hu IFN-o( [Ly], IFN) on the human HCC cell line PLC/PRF/5 have been 
examined. In vitro, PLC/PRF/5 cells were sensitive to the 
antiproliferative effects of IFN, growth inhibition being noted at 
concentrations as low as 1.25 IU/ml. Athymic mice with 
PLC/PRF/5-derived tumour xenografts were treated daily with IFN or a 
saline control. An IFN dose of 2 x 10 IU/day was found capable of 
significantly reducing tumour growth rate and prolonging mouse 
survival. Further studies to examine the mechanisms involved in 
growth inhibition in vivo demonstrated that IFN was capable of 
inducing the activity of the enzyme 2,5-oligoadenylic acid (2,5 A) 
synthetase, a potent inhibitor of protein synthesis, in tumour 
xenografts but not in mouse tissue, and that IFN significantly 
enhanced the membrane display of HLA class I glycoproteins on tumour 
cells, though histology did not reveal any increase in tumour 
infiltration by host lymphocytes. It is concluded that IFN exerts 
potent growth inhibiting effects on the PLC/PRF/5 cell line both in 
vitro and in vivo and its mode of action in the athymic mouse system 
appears to be predominantly mediated by a direct antiproliferative 
effect on tumour cells.
INTRODUCTION
The interferons are a family of proteins and glycoproteins which were 
first described as naturally occurring anti-viral agents (Isaacs and 
Lindenmann, 1957) but which have since been shown to possess a variety 
of immunoregulatory and antiproliferative properties (Gresser and 
Tovey, 1978; Borden and Ball, 1981; Steihm et al, 1982). It is
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because of these latter properties, and because of increasing 
availability brought about predominantly by advances in recombinant 
DNA technology, that the interferons are now the focus of much 
attention as potential anti-cancer agents, and their role in the 
treatment of a variety of malignancies is currently being explored 
(for reviews see Borden, 1984; Krown, 1986; Golomb, 1986). This 
chapter reports on studies examining the effects of IFN on the growth 
of the human HCC cell line PLC/PRF/5 both in vitro and when 
established as a tumour xenograft in athymic mice, and also reports on 
the possible mechanisms whereby interferons may exert cytotoxic 
effects in this animal model.
MATERIALS AND METHODS 
Interferon
All studies were performed using human lymphoblastoid IFN 
(Hu IFN-o<[Ly], "Wellferon", Wellcome Research Laboratories,
Beckenham, UK). This product is a mixture of at least eight 
-interferons and is produced by the stimulation of suspension 
cultures of the Namalwa lymphoblastoid cell line by Sendai virus.
In vitro studies
The PLC/PRF/5 cell line was used throughout and cultured as described 
in Chapter 4. For these experiments, cells were harvested by mild 
trypsinisation and suspended in modified Eagle's medium (MEM) at a
5
concentration of 1 x 10 cells/ml. Two hundred jil aliquots were 
dispensed into flat-bottomed microtitre plates (Nunc). Interferon was 
diluted in MEM and added to the wells to yield final well 
concentrations of IFN ranging from 1.25 to 5 x 10 IU/ml. Interferon
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which had been inactivated by incubation with 0.1 mg/ml of trypsin for 
one hour at 37°C was used as an internal control. Cells were 
incubated with IFN for times ranging from 24 to 72 hours and then one
3
pCi of tritiated thymidine ([ H] thy: Amersham International PLC, UK) 
was added to each well. After a further 18 hour incubation, cells 
were washed three times to remove non-incorporated radioactivity and 
harvested by trypsinisation and aspiration onto glass fibre discs by 
means of a Titertek cell harvester (Flow Laboratories Ltd, UK). Discs 
were air-dried and radioactivity counted. Each experiment was 
performed in triplicate.
Animal studies
Tumour xenografts derived from the PLC/PRF/5 cell line were grown in
athymic mice as described in Chapter 4. Mice with established growing
2tumours of base area 20-60 mm were allocated to receive
subcutaneously daily either 200 pi of sterile phosphate-buffered
c
saline (PBS), 200 jil of PBS containing 1 x 10 IU of IFN or 200 pi of
5
PBS containing 2 x 10 IU of IFN. Each group contained eight animals 
and they were treated daily till death. Tumour size was assessed 
weekly by measuring tumour base area and by measuring serum AFP 
concentrations, as described in Chapter 4.
In a separate experiment designed to examine the mechanisms by which 
IFN might be cytotoxic in this animal model, two groups, each 
containing five mice with growing tumour xenografts, were treated
5
subcutaneously daily with either 200 pi of PBS containing 2 x 10 
IU of IFN or 200 pi of PBS alone. At the end of 14 days treatment, 
all animals were sacrificed and their tumours and livers immediately 
excised.
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A portion of each tumour was fixed in 10% formaldehyde solution and 
embedded in paraffin for histological examination. The remaining 
tumour and all specimens of liver were snap-frozen in liquid nitrogen 
and stored at -70°C until examined.
Cryostat sections, 5 yim thick, were cut from snap-frozen specimens of 
tumour and liver and examined for HLA class I glycoprotein display 
using an indirect immunofluorescence technique. After fixation in 
chlorofonv'acetone solution (1:1 v/v), sections were washed in PBS for 
15 minutes and then incubated for 30 minutes at room temperature in a 
humidified chamber with 15 yil of either W6/32, an anti-HLA class I 
glycoprotein monoclonal antibody (Sera-Lab, Sussex, UK) (Barnstaple et 
al, 1978), or mouse serum. Sections were then washed in PBS for 30 
minutes and 15 |il of fluorescein-conjugated rabbit anti-mouse IgG 
(Dakopatts, Bucks, UK) diluted 1:20 was added as second layer reagent 
for a further 30 minutes. Following a final 30 minute wash in PBS, 
slides were mounted in PBS-glycerol with p-phenylene diamine and 
examined using a Zeiss fluorescence microscope equipped with an IV/2 
epifluorescence condenser and Zeiss photometer 03, HLA class I 
glycoprotein staining intensity being measured semi-quantitatively as 
previously described by Montano et al (1982). The result for each 
section was a mean of the measurements of staining intensity from 
eight randomly selected areas on each slide.
The activity of the enzyme 2,5-oligoadenylic acid (2,5 A) synthetase, 
a potent inhibitor of protein synthesis, was measured in tumour 
xenografts and mouse liver using a modification of the method of Minks 
et al (1979) as follows. Tissue extracts were prepared by
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homogenising samples in a buffer containing 0.5% Nonidet-P40, 7 mM 
2-mercaptoethanol and 20 mM Hepes, pH 7.5. The homogenate was 
centrifuged and the supernatant removed. Protein concentration was 
measured by the method of Lowry et al (1951) and the supernatant was 
then stored at -70°C until assayed. One hundred jil of thawed extract 
was added to 50 |il of poly (rI):poly (rC)-agarose beads (PL 
Biochemicals, UK) which had been equilibriated in buffer A: 10 mM 
Hepes, pH 7.6, 50 mM KCl, 2 mM Mg (QAc^, 7 mM 2-mercaptoethanol, and 
20% glycerol. Beads were incubated with tissue extracts for 30 
minutes at 30°C and then washed three times in buffer A. Beads were 
then incubated for 20 hours at 30°C in 200 jil of a reaction mixture 
containing 20 mM Hepes, pH 7.6, 40 mM KCl, 25 mM Mg (QAc^/ 7 mM 
2-mercaptoethanol, 5 mM ATP, 10 mM creatine phosphate, 0.32 mg/ml 
creatine kinase, 0.1 mg/ml poly (rI):poly (rC) (all Sigma Chemical Co 
Ltd, UK) and 0.1 jiCi [^H] ATP (Amersham International PLC, UK). The 
reaction was terminated by heating to 90°C for five minutes.
3
[ H]-labelled 2,5A was then purified by DEAE cellulose chromatography 
and the radioactivity of the entire sample was measured after dilution 
in a liquid scintillant.
Statistical analysis
The unpaired Student's t-test and the log-rank test were used as 
appropriate. Survival curves were drawn up by the Kaplan-Meier 
method.
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RESULTS
3
Effect of IFN on [ Hj thymidine uptake by PLC/PRF/5 cells 
3
The uptake of [ H] thymidine by PLC/PRF/5 cells was inhibited by IFN 
in a dose dependent manner (Figure 5 (i)). The degree of inhibition 
noted after 24 hours incubation with IFN could not be increased by 
more prolonged incubation (data not shown). Inhibition of DNA 
synthesis was noted at the lowest IFN concentration studied, 1.25
3
IU/ml, and a 50% inhibition of [ H] thymidine uptake was noted at IFN 
concentrations of around 1000 IU/ml. In contrast, trypsin-inactivated
3
IFN had no effect on [ H] thymidine uptake by PLC/PRF/5 cells.
Effects of IFN on HCC xenograft growth
As assessed by measuring tumour base area (Table 5 (i)) or serum AFP 
concentration (Table 5 (ii)), IFN produced a dose-dependent inhibition 
in the growth of HCC xenografts in athymic mice. In the animals
5
treated with 2 x 10 IU/day of IFN, tumours grew significantly more 
slowly than those in control animals. Interferon also increased the 
length of survival of tumour bearing animals (Figure 5 (ii)). Again, 
the effect was dose-related, and the duration of survival of mice
5
treated with 2 x 10 IU/day of IFN was significantly longer than that 
of control animals (p=0.03).
Effects of IFN on HLA class I glycoprotein display, tumour histology 
and 2,5A synthetase activity
HLA class I glycoprotein display was increased approximately six-fold 
by IFN treatment. Immunofluorescence intensity increased from 4.2 + 
0.3 arbitrary units in control animals to 24.8 + 0.6 units in the 
tumours of IFN-treated animals (mean + SEM, p<0.05). Apart from size
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Figure 5 (i)
EFFECT OF IFN ON THE UPTAKE OF [3r ] THYMIDINE BY PLC/PRF/5 CELLS. 
Results are expressed as the mean + SEM of 5 experiments. Control
3
[ H] thymidine uptake is the uptake seen in cells incubated in the 
absence of IFN.
Table 5 (i)
TUMOUR GROWTH RATES OF CONTROL AND IFN-TREATED MICE.
Treatment group
Rate of increase in tumour base area 
2
(mm /week) (mean + SEM)
Control 29.2 + 5.28
IFN 1 x 105 IU/day 23.7 + 8.52a
IFN 2 x 105 IU/day 13.8 + 4.22b 'c
a p = 0.59 vs control growth rate
p = 0.04 vs control growth rate
c p = 0.32 vs IFN 1 x 105 IU/day growth rate
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Table 5 (ii)
WEEKLY SERUM AFP CONCENTRATIONS (IU/ml) OF CONTROL AND IFN-TREATED 
MICE DURING THE FIRST FOUR WEEKS OF STUDY (mean + SEM).
Weeks of therapy Controls
IFN c
(1 x 10 IU/day)
IFN c
(2 x 10 IU/day)
0 2236 + 1141 1576 + 557 1928 + 682
1 4804 + 1699 2751 + 973 2337 + 826
2 8315 + 2939 3704 + 1017 2914 + 883
3 18378 + 5244 10018 + 3350 5425 + 3086a
4 40168 + 12231 36723 + 11127 10016 + 5107a
a
p<0.05 vs control group
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Figure 5 (ii)
KAPLAN-MEIER SURVIVAL CURVES OF CONTROL AND IFN-TREATED MICE.
The median duration of survival of animals treated with IFN 1 x 10“* 
IU/day was not significantly longer than the control group (53 vs 43 
days, p = 0.08). Those treated with 2 x 10"* IU/day of IFN survived 
significantly longer than controls (61 days, p = 0.03).
differences, there were no apparent macroscopic or light-microscopic 
differences between the tumours of control and IFN treated animals.
In particular there were no obvious differences in the degree of local 
invasivness, the intensity of the inflammatory cell infiltrate or the 
degree of tumour necrosis. IFN produced a marked rise in 2,5A 
synthetase activity in the tumours of treated animals (Figure 5 (iii), 
p<0.05). The slight increase in enzyme activity observed in the 
livers of treated animals did not achieve statistical significance.
DISCUSSION
These experiments demonstrate that human lymphoblastoid IFN produces 
dose-dependent inhibition of the in vitro and in vivo growth of the 
PLC/PRF/5 cell line. The in vitro data indicate that o(-IFN is 
capable of a direct inhibitory effect on cell growth, which is 
manifest even at low IFN concentrations, a finding previously noted by 
Desmyter et al (1981) and recently confirmed by Motoo et al (1986), 
who, like Hinoue (1985), also noted in vitro sensitivity to JB-IFN.
5
In vivo, a daily ©C-IFN dosage of 2 x 10 IU/day was found able to 
inhibit tumour growth and prolong the survival of mice with 
PLC/PRF/5-derived tumour xenografts. This dose, as assessed by the 
calculations of Freireich et al (1966), which take into account 
species differences in surface area to weight ratio, is equivalent to
g
approximately 20 x 10 IU/day in man, and is far in excess of the
5
thrice weekly dosage of 10 IU which Desmyter et al (1981) found 
incapable of inhibiting the development of HCC xenografts in nude mice 
injected with PLC/PRF/5 cells. Similarly, the use by Hinoue (1985) of 
only 2 x 10^ IU/day of |?-IFN may explain his finding of only brief 
initial inhibition of PLC/PRF/5 tumour xenograft growth.
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Figure 5 (iii)
LIVER AND TUMOUR 2,5A SYNTHETASE ACTIVITIES IN CONTROL AND IFN-TREATED 
MICE.
These studies, and those of others (Balkwill et al, 1983), suggest 
that in the athymic mouse system, the growth of human tumour 
xenografts is primarily inhibited by the direct antiproliferative 
effects of human IFN on cell growth. Human o<-iFN was found to be 
capable of producing large increases in the activity of the enzyme 
2,5A synthetase only in tumour xenografts and not in mouse tissue, 
thus demonstrating the potential of this IFN preparation to inhibit 
tumour growth directly, by inhibition of tumour protein synthesis.
The role of the immunomodulatory effects of IFNs on the growth of 
human tumours is difficult to study in the athymic mouse because of 
its congenitally deficient immune system (Kindred, 1978) and because 
of the HLA incompatibility between mouse and human tissue. Though IFN 
produced significant increases in the display of HLA class I 
glycoprotein in tumour xenografts, for the reasons previously stated, 
it is unlikely that this mechanism played a role in the observed 
growth inhibitory effects of IFN on tumour xenografts. However, in an 
immunocompetent and HLA-matched system, it is possible that the 
enhancement of tumour HLA class I glycoprotein display by IFN, thus 
making malignant cells more susceptible to immune lysis by T-cell 
mediated pathways (Zinkernagel and Doherty, 1979), may assume some 
importance in tumour growth inhibition. It is of note that IFNs, as 
assessed by serum 2_micro9l°frulin levels, are capable of increasing 
HLA class I glycoprotein display in cancer patients (Borden et al, 
1982; Lucero et al, 1982).
Though athymic mice have a T-cell deficient immune system, they have a 
normal population of Natural Killer (NK) cells (Herberman, 1978), and
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it has been previously shown that athymic mouse NK cell activity is 
modulated by mouse IFN, and that this system is important in 
inhibiting the tumourogenicity of PLC/PRF/5-derived tumour xenografts 
(Shouval et al, 1983). Though the effects of IFN.on mouse NK cell 
activity have not been examined, it is unlikely that IFN-induced 
enhancement of NK cell activity was important in producing the 
inhibitory effect on tumour xenograft growth noted in this study, as 
it has been previously shown that human IFN has no effect on athymic 
mouse NK cell activity (Balkwill et al, 1983). It is of interest 
however, that in the same study, Balkwill et al (1983) demonstrated 
that mouse IFN could inhibit the growth of human breast cancer 
xenografts. This was thought to be primarily due to a stimulating 
effect of mouse IFN on mouse NK cell activity, as tumour xenograft 
2,5A synthetase activity was unchanged by mouse IFN. It is therefore 
possible that in this animal model the administration of both human 
and mouse IFNs in combination could produce a greater anti-tumour 
effect than either alone, both by directly inhibiting tumour xenograft 
protein synthesis and by enhancing mouse NK activity.
Clinical trials using IFNs for the treatment of HCC in man have begun 
and their results will be of interest, as both the various 
immunomodulatory effects of IFNs, which cannot be studied adequately 
in the immunodeficient athymic mouse model, and their direct 
antiproliferative actions, may both be operational. In Chapter 6 the 
effects of IFN on NK cell actvity in patients with HCC are examined 
and the few small clinical trials so far published examining the 
effects of IFNs as sole therapy for HCC are discussed in detail in 
Chapter 2.
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CHAPTER SIX
NATURAL KILLER CELL ACTIVITY IN HEPATOCELLULAR CARCINOMA:
IN VITRO AND IN VIVO RESPONSES TO HUMAN LYMPHOBLASTOID INTERFERON
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■ABSTRACT
Natural killer (NK) cell cytotoxicity has been measured in patients 
with HCC and in appropriate control subjects, and the effects of in 
vitro and in vivo administration of human lymphoblastoid interferon 
(Hu IFN-0([Ly], IFN) on NK cell activity determined.
The NK cell activity of HCC patients was significantly lower than that
in patients with cirrhosis or healthy control subjects. Reduced NK
cell activity in HCC did not correlate significantly with either serum
AFP concentration or patient WHO performance grade. NK cell
cytotoxicity in all groups could be increased by prior incubation of
effector cells with IFN, but this was significant only in HCC
patients, where 10 IU/ml of IFN increased NK cell cytotoxicity from
36.9 + 10% to 52.8 + 8.2% (p<0.05, effector:target ratio = 50:1).
Further increases in IFN concentration failed to further increase NK
cell activity. NK cell cytotoxicity was measured before and 24 hours 
2
after 2.5 mU/m was given subcutaneously to four HCC patients. NK 
cell cytotoxicity rose from 27.5 + 8.6% to 60.9 + 5.2%
(effector:target ratio = 50:1, mean + SEM, p = 0.05).
INTRODUCTION
NK cells are large granular mononuclear cells which possess the 
ability to spontaneously lyse a variety of target cells in vitro, and 
they may play a role in the host defence against tumours and viral 
infections (Herberman, 1983; Bukowski et al, 1983; Gorelik and 
Herberman, 1986). NK cell cytotoxicity has been reported to be 
depressed in patients with advanced cancers (Pross and Baines, 1976;
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Takasugi et al, 1977; Kadish et al, 1981; Steinhauer et al, 1982), 
including HCC (Son et al, 1982; Hirai et al, 1986), though the 
underlying mechanisms are currently unclear.
In this study the NK cell activity of HCC patients has been measured, 
and because AFP has potent immunological effects in vivo (Murgita and 
Tomasi, 1975a; Murgita and Tomasi, 1975b;Yamada and Hayami, 1983), the 
relationship between NK cell cytotoxicity and serum AFP concentration 
has been examined. In addition, as IFNs play an important role in 
modulating NK cell activity (Herberman et al, 1979; Minato et al, 
1980), and because the IFN/NK cell system appears important in 
inhibiting the tumourogenicity of HCC cell lines in athymic mice 
(Shouval et al, 1983), the effects of in vitro and in vivo IFN 
administration on NK cell activity in HCC patients has been examined.
PATIENTS AND METHODS 
Patients
Seventeen untreated patients with histologically proven HCC (15 of 
whom had an underlying cirrhosis) were studied, and their NK cell 
activity was compared with cirrhotic patients with no evidence of HCC 
(n = 13) and with control subjects (either laboratory staff or 
relatives of HCC patients, n = 12) with normal serum liver function 
tests. All groups were equally matched with respect to age (HCC 
patients 61.5 + 11.3 years, cirrhotic patients 55.0 + 12.4 years, 
control subjects 57.0 + 16.0 years; mean + SD). The types of 
cirrhosis and the clinical condition (World Health Organisation, 1979) 
of the patients in the HCC and cirrhotic groups are listed in 
Table 6 (i). All subjects had serum AFP concentrations measured by
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Table 6(i)
TYPES OF CIRRHOSIS, PERFORMANCE GRADES, AND SERUM AFP CONCENTRATIONS 
IN HCC AND CIRRHOTIC PATIENTS.
HCC Patients 
(n = 17)
Cirrhotic Patients 
(n = 13)
Types of cirrhosis
Cryptogenic 8 5
HBsAg positive 4 3
Alcoholic 1 4
Other 2 1
Non-cirrhotic 2 0
WHO Performance Grade
0 2 0
1 7 2
2 5 6
3 2 5
4 1 0
Serum AFP (IU/ml)
<10 4 10
10 - 100 4 3*
101 - 1000 4 0
>1000 5 0
* all less than 20 IU/ml
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radioimmunoassay on the day of assay of NK cell cytotoxicity. As 
assessed by a variety of imaging techniques, all HCC patients had 
tumour involving both lobes of the liver, and two patients had 
metastatic HCC.
Assays of NK cell activity
51NK cell cytotoxicity was measured in a short incubation Chromium 
release assay as follows:
Effector Cells
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh 
heparinised whole blood by centrifugation on Ficoll-Hypaque 
(Lymphocyte separating medium, Flow Laboratories, UK). Mononuclear 
cells were collected from the interface, washed three times, and 
suspended in RPMI 1640 medium supplemented with 10% v/v foetal calf 
serum, L-glutamine and antibiotics (all Gibco Ltd, UK).
Target Cells
The erythroleukemia cell line K562 was used as target cell throughout. 
Cells were grown in RPMI 1640 medium supplemented as above, and 
subcultured once weekly. On the day of assay, cells were harvested by
gentle agitation, washed in RPMI 1640, suspended at a concentration of
6 512.5 x 10 /ml and then incubated with Na2< Cr)°4 (Amersham
International PLC, UK) for one hour at a concentration of 100 jiCi/ml
of cell suspension. Cells were then washed five times in RPMI 1640
4
and resuspended at a concentration of 2 x 10 cells/ml.
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Assay
51Five-hundred jil of Cr labelled K562 cells were incubated m
10.5 mm x 63.5 iran test tubes with 500 jil of PBMCs suspended at various
concentrations, to yield effector:target ratios of 100:1, 50:1 and
10:1. Cells were incubated at 37°C in a humidified atmosphere of 95%
51air and 5% CC^ for four hours. To calculate spontaneous Cr release
some tubes in each experiment contained only target cells and medium,
51and to calculate maximal Cr release others contained target cells 
and 500 jil of 1% Triton-XlOO detergent. After incubation, cells were 
centrifuged at 1500 rpm for five mintues and 500 |il aliquots of 
supernatant were then removed for gamma counting. Each experiment was 
performed in triplicate and percentage cytotoxicity calculated 
according to the formula:
% cytotoxicity = mean test counts - mean spontaneous counts x 100 
mean maximum counts - mean spontaneous counts
51 51Spontaneous Cr release was always less than 20% of maximal Cr
release and the variability of triplicate determinations was
consistently less than 10%.
In vitro and in vivo effects of interferon
As in Chapter 5, human lymphoblastoid interferon (Hu IFN- c<[Ly], IFN;
"Wellferon", Wellcome Research Laboratories, UK) was used throughout.
The in vitro effects of IFN were studied in five patients from each
group by pre-incubating their PBMCs (4 x 10 /ml) for three hours in
concentrations of IFN ranging from 0 - 1000 IU/ml. Cells were then 
51washed and the Cr release assay performed as above at an
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effector:target ratio of 50:1.
The in vivo effects of IFN were studied in four patients taking part
in pilot chemotherapy studies examining the toxicity and efficacy of
IFN treatment in HCC. Each patient's NK cell cytotoxicity was assayed
as above immediately before and 24 hours after a subcutaneous
2
injection of 2.5 megaunits/m of lymphoblastoid IFN.
Statistical analysis
All assays were performed in triplicate and mean values determined. 
Experimental results are expressed as mean + SEM. All statistical 
tests were non-parametric. The significance of differences between 
groups was determined using the unpaired or paired Wilcoxon's rank sum 
tests as appropriate. The significance of correlations was tested 
using Kendall's rank correlation test.
RESULTS
Figure 6 (i) illustrates the NK cell cytotoxicity of each group at 
effector:target ratios of 100:1, 50:1 and 10:1. There was no 
significant difference in NK cell cytotoxicity between healthy 
controls and patients with cirrhosis at any effector:target ratio. At 
all effector:target ratios however, NK cell cytotoxicity was 
significantly reduced (p<0.05) in HCC patients when compared to either 
cirrhotic patients or healthy subjects (e.g. at 50:1, % cytotoxicity 
HCC patients = 26.3 + 3.7%, cirrhotic patients = 45.6 + 2.2%, healthy 
controls = 57.8 + 4.6%. mean + SEM). NK cell cytotoxicity in HCC 
patients did not correlate significantly with either serum AFP 
concentration (Figure 6 (ii); Kendall's coefficient of correlations 
-0.103, p>0.5) or WHO performance grade (data not shown; Kendall's
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SCATTER DIAGRAM OF THE RELATIONSHIP BETWEEN SERUM AFP CONCENTRATION 
AND NK CELL CYTOTOXICITY (EFFECTOR:TARGET RATIO = 50:1) IN HCC 
PATIENTS.
coefficient of correlation = +0.15, p>0.31). The effect of tumour 
burden on NK cell cytotoxicity could not be determined as, with the 
exception of two patients, all had approximately similar tumour 
burdens.
In vitro, IFN produced increases in NK cell cytotoxicity in all groups 
(Figure 6 (iii)). At an IFN concentration of 10 IU/ml the percentage 
increases in NK cell cytotoxicity were greatest in HCC patients 
(77.9 + 32.4%, mean + SEM; p<0.01 v baseline values). Percentage 
increases in cirrhotic patients (13.7 + 7.5%) and control subjects 
(32.8 + 16.9%) were smaller and the absolute values were not 
statistically significantly greater than baseline values. Increasing 
IFN concentration above 10 IU/ml did not result in further large 
increases in NK cell cytotoxicity in any of the groups.
In the four HCC patients given IFN by subcutaneous injection, NK cell 
cytotoxicity rose significantly from 27.5 + 8.6% to 60.9 + 5.2% 
(effector:target ratio = 50:1, mean + SEM, p = 0.05; Figure 6 (iv)).
DISCUSSION
The results of this study, using more appropriate control groups, 
confirm and extend previous observations of diminished NK cell 
cytotoxicity in HCC patients (Son et al, 1982; Hirai et al, 1986).
The aetiology and pathogenesis of this defect are currently unclear. 
Though NK cell cytotoxicity has been variously reported to be low 
(Charpentier et al, 1984; James and Jones, 1985), normal (Vierling et 
al, 1977; Chisari et al, 1981; Serdengecti et al, 1981) or increased 
(Dienstag et al, 1982) in patients with a variety of chronic liver
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.THE EFFECT OF IN VIVO ADMINISTRATION OF HUMAN LYMPHOBLASTOID 
INTERFERON ON THE NK CELL CYTOTOXICITY OF PBMCs ISOLATED FROM HCC 
PATIENTS (n = 4; effector:target ratio = 50:1).
diseases, it seems unlikely that the low NK cell cytotoxicity in HCC 
patients is secondary to the presence of underlying chronic liver 
disease per se, as the control group of patients with broadly 
comparable chronic liver diseases had normal NK cell activity. Though 
AFP has potent immunomodulatory effects (Murgita and Tomasi, 1975a; 
Murgita and Tomasi, 1975b), and may cause reduced NK cell activity in 
vivo by virtue of the generation of suppressor cells to NK cells 
(Yamada and Hiyami, 1983), no correlation could be found between serum 
AFP concentration in HCC patients and their NK cell activity, and it 
is therefore unlikely that AFP is of major importance in the 
pathogenesis of the reduced NK cell cytotoxicity in these patients.
The possibility that other serum factors may be involved has been 
examined by Son et al (1982), who found that sera from HCC patients 
could not inhibit the NK cell cytotoxicity of PBMCs isolated from 
healthy control subjects.
Reduced numbers of NK cells within the PBMC population of HCC patients 
cannot be excluded as a cause of the reduced NK cell cytotoxicity 
observed and further studies are needed which define, using monoclonal 
antibodies which are relatively specific for cells with NK function 
(for reveiw see Gorelik and Herberman, 1986), the size of the NK cell 
population of patients with HCC and chronic non-malignant liver 
diseases. Normal numbers of circulating NK cells, in the presence of 
reduced NK cell cytotoxicity, have however been found in studies in 
patients with advanced cancers (Steinhauer et al, 1982), and in 
patients with primary biliary cirrhosis (James and Jones, 1985).
Diminished endogenous IFN production (Funa et al, 1983; Funa et al, 
1984) and diminished responsiveness of NK cells to IFN (Funa et al,
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1984) have been proposed as two of several possible mechanisms 
resulting in reduced NK cell activity in cancer patients. Though 
endogenous IFN production has not been measured in this study, it is 
unlikely that diminished IFN-responsiveness is responsible for the low 
NK cell activity in HCC patients, as NK cell activity was 
significantly enhanced both in vitro and in vivo by low doses of IFN. 
The dose of IFN given to the HCC patients would be expected to produce 
peak plasma IFN concentrations of only 20-30 IU/ml (Gutterman et al,
1982).
Though it is unclear whether the reduced NK cell cytotoxicity in HCC 
patients has any deleterious effect on tumour growth and metastatic 
spread, there is considerable experimental evidence that NK cell 
activity may be important in host resistance against the growth of 
primary tumours and metastatic disease (Gorelik and Herberman, 1986). 
These factors, taken in conjunction with animal studies demonstrating 
that the IFN/NK cell system is of importance in inhibiting the 
tumourogenicity and invasiveness of HCC cell lines (Shouval et al,
1983), and the finding that IFN can prolong the survival of mice with 
xenografts derived from HCC cell lines (see Chapter 5), suggest that 
IFNs, by virtue of their direct antiproliferative and immunomodulatory 
effects, may be worthy of evaluation in the treatment of HCC. As 
discussed in detail in Chapter 2, preliminary results in small numbers 
of patients have already been reported. While immunostimulation has 
been noted during IFN treatment for HCC (Nair et al, 1985), responses 
to therapy have so far been very disappointing (Nair et al, 1985;
Sachs et al, 1985; Forbes et al, 1985).
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CHAPTER SEVEN
HUMAN HEPATOCELLULAR CARCINOMA TUMOUR XENOGRAFTS:
THEIR ANDROGEN RECEPTOR STATUS AND GROWTH RESPONSES TO CASTRATION
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ABSTRACT
Castrated or sham-operated male athymic mice were inoculated with 
cells from the human hepatocellular carcinoma cell line PLC/PRF/5. 
Fewer castrated than control animals developed tumours and their 
tumours appeared at later times and grew more slowly, though the small 
differences noted did not achieve statistical significance. Androgen 
receptors were assayed in nuclei obtained from three separate liver 
cancer cell lines and from normal adult human liver. Similar 
concentrations ranging from 235-550 fMol mg~^ DNA of nuclear androgen 
receptors were detected in all tissues. Low percentages of androgen 
receptors were retained on DNA-cellulose. Although the presence of 
receptors implies the potential for metabolic effects of androgens ih 
normal and malignant liver, our in vivo studies suggest that 
castration does not alter significantly the development and growth of 
hepatocellular carcinoma xenografts in athymic mice.
INTRODUCTION
For many years there has been strong evidence from animal studies that 
androgenic steroids may play a role in the development of 
spontaneous and chemically induced HCCs (Andervont, 1951; 
Vesselinovitch and Mihailovich, 1967; Reuber, 1969), and there is 
circumstantial evidence in man that androgenic steroids may play a 
role in the development of HCC. This is evidenced by the multiple 
case reports of HCC developing in patients on long-term androgen 
therapy (Barnstein et al, 1971; Johnson et al, 1972; Bruguera, 1975; 
Boyd and Mark, 1977), and by the fact that in all areas of the world 
HCC is a disease with a definite male preponderance (Peters, 1976).
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Recently this evidence has been further strengthened by the finding of 
androgen receptors in human HCC tissue (Iqbal et al, 1983; Nagasue et 
al, 1985; Ohnishi et al, 1986). It is therefore possible that 
androgens may exert metabolic effects on human HCC in vivo, and that 
androgenic manipulation may play some role in the treatment of this 
malignancy.
In this chapter the effects of castration on the development and 
growth of human HCC tumour xenografts in athymic mice are reported, as 
are androgen receptor measurements in normal adult human liver and in 
tumour xenografts derived from three different human HCC cell lines.
METHODS
Effects of castration
Sexually mature male athymic mice were either castrated or had sham 
surgery (scrotal incision and suturing). After seven days of 
antibiotic treatment, serum testosterone levels were measured by 
radioimmunoassay (Dyas et al, 1979) in the 11 animals in each group. 
Mice were then irradiated and inoculated with PLC/PRF/5 cells as 
described in Chapter 4, and observed weekly for evidence of tumour 
development. Tumour growth was then measured weekly for four weeks by 
using precision calipers and by measuring serum AFP concentration 
(Chapter 4).
Androgen receptor analyses
Tumour xenografts of the PLC/PRF/5, SK-Hep-1 and Mahlavu cell lines 
were grown in male athymic mice as previously described and allowed to 
grow until they weighed at least 1.5 grams. Animals were then
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sacrificed and the tumours immediately excised and frozen at -70°C. 
Normal adult liver was obtained for analysis from two brain-dead 
subjects (one male, one female) donating organs for transplantation, 
and tissue was likewise frozen at -70°C until assayed, usually within 
two weeks of collection.
Nuclei were purified by the method of Davies and Griffiths (1975). 
Specific androgen receptor (AR) sites were assayed in whole nuclei 
using (1, 2, 4, 5-^H) 5 o<-dihydrotestosterone ([^H] DHT: 110 Ci/mMol, 
Amersham International PLC, UK) as ligand by the protamine sulphate 
precipitation method of Davies et al (1977). Concentrations of AR
3
were calculated as fMol of [ H] DHT specifically retained per mg 
nuclear DNA. DNA was estimated throughout by the method of Burton 
(1956). The preparation of DNA-cellulose was carried out as described 
by Alberts and Herrick (1971) with minor modifications. Salmon testis 
DNA (1.5 mg/ml) was mixed with extensively washed, neutralised, 
lyophilised Whatman Fll cellulose (approx. 0.5 g/ml) to generate a 
thick paste which was lyophilised, ground, dried thoroughly, suspended 
in tris-HCl (10 mMol/1, pH 7.4) containing EDTA 1 mMol/1, washed twice 
in this buffer to remove free DNA and then stored as a frozen slurry 
in this buffer containing NaCl (150 mMol/1) until used. The average 
incorporation of DNA was 480 pg per packed ml, i.e. 33% of the input 
DNA was adsorbed onto cellulose.
Analysis of the DNA-binding capacity of AR was carried out at 4°C as 
follows. A slurry of DNA-cellulose diluted 10-fold in tris-HCl (10 
mMol/1, pH 7.4) containing EDTA (1 mMol/1) and NaCl (50 mMol/1) was 
packed into 1 ml volume syringes (diameter 5 mm) to a bed volume of . 
0.25-0.30 ml under gravity. Columns were equilibrated in tris-HCl (10
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mMol/1, pH 7.4) containing EDTA (0.1 mMol/1) dithiothreitol (0.25 
mMol/1) and NaCl (50 mMol/1) (buffer A). Receptor preparations, 
previously labelled with [ H] DHT in the presence and absence of a 
100-fold higher concentration of radioinert DHT, were applied to 
columns in 200 pi. Columns were washed in approximately 30 bed 
volumes (7.5-9.0 ml) of buffer A until a constant background of 
radioactivity (360-400 dpm/ml) was obtained. Specifically retained 
[ H] DHT-AR complexes were then eluted with six successive 500 pi 
aliquots of buffer A but containing 500 mMol/1 NaCl and 0.2 mg/ml 
bovine serum albumin. Columns were eluted at three ml/hour and 500 pi 
aliquots were collected into scintillation vials and radioactivity 
determined.
Statistical analyses
The chi-squared test with Yates correction for small numbers and the 
unpaired Wilcoxon's rank sum test were used where appropriate.
RESULTS
Effects of castration
Serum testosterone levels were significantly lower in castrated 
animals than in controls (60 + 11 vs 248 + 13 ng/1, mean + SD, 
p<0.01). One mouse in the castrated group died within two weeks of 
cell inoculation and was not included in experimental evaluation.
There was no macroscopic evidence of tumour development at death.
Seven of the 10 castrated animals (70%) and eight of the 11 mice in 
the control group (73%) developed tumours (p = not significant). 
Similarly there was no significant difference between the two groups
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in the time between tumour cell inoculation and macroscopic tumour
development. Two weeks after inoculation four of the seven tumours in
the castrated animals and six of the eight in the control animals had
developed (Table 7 (i)). No significant differences existed between
the groups with respect to rate of increase in tumour xenograft base
2
area (control animals 49.1 + 9.6 mm /week vs castrated animals 44.0 +
220.5 mm /week, mean + SD) and at the end of the four week observation
period both groups were similar with respect to tumour base area
2 2 (control animals 164.8 + 92 mm vs castrated animals 145.2 + 61.5 mm ,
mean + SD, p = NS) and serum AFP concentration (control animals 25744
+ 16813 IU/ml vs castrated animals 21985 + 1328 IU/ml, mean + SD, p =
NS).
Androgen receptor studies
Nuclear AR were found in normal human liver and the HCC xenografts 
derived from the PLC/PRF/5, SK-Hep-1 and Mahlavu cell lines (Table 7 
(ii) and Figure 7 (i)). The AR concentrations for the tumour 
xenografts fell between those observed for the samples of normal 
liver. The Kd values for AR in tumour xenografts fall into the range 
noted for receptors in classically androgen-dependent tissues, but 
those for normal human liver are somewhat high. The results of the 
DNA-cellulose binding assay are shown in Figure 7 (ii). The absence
3
of a radioactivity peak during the high molarity salt elution of [ H] 
DHT-AR complexes which had been incubated in the presence of
3
unlabelled DHT demonstrates the binding specificity of [ H] DHT to AR. 
To determine functionality of receptors at a preliminary level the 
capacity to associate with DNA was investigated. High-salt buffers 
eluted 12.2% of specific receptors from DNA-cellulose indicating that 
more than 85% of input AR was not retained by DNA.
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Table 7 (i)
TIME TAKEN POST TUMOUR CELL INOCULATION TO MACROSCOPIC TUMOUR 
DEVELOPMENT IN CONTROL AND CASTRATED ANIMALS.
Week No. of mice with tumours/total no. developing tumours 
Control Castrated
1 0/8 0/8
2 6/8 4/7
3 8/8 6/7
4 8/8 7/7
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Table 7 (ii)
ANDROGEN RECEPTOR CONCENTRATIONS AND DISSOCIATION CONSTANTS (Kd) FOR 
ADULT HUMAN LIVER AND EACH HCC CELL LINE.
Tissue AR (£Mol mg 1 DNA)
_1
Kd (nmol 1 )
Normal liver (male donor) 550 14.7
Normal liver (female donor) 235 7.3
PLC/PRF/5 xenograft 401 5.4
SK-Hep-1 xenograft 375 9.0
Mahlavu xenograft 303 9.6
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Figure 7 (i)
SATURATION ANALYSIS OF [3H] DHT BINDING TO NUCLEAR AR FROM NORMAL 
ADULT LIVER (A) AND TUMOUR XENOGRAFTS DERIVED FROM THE PLC/PRF/5 (B), 
AND SK-HEP-1 (C) CELL LINES.
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Figure 7 (ii)
ELUTION OF [3H ] dHT-AR COMPLEXES (FROM A PLC/PRF/5-DERIVED TUMOUR 
XENOGRAFT) FROM DNA-CELLULOSE BY 500 mM NaCl.
DISCUSSION
The association of HCC with male sex and with androgenic steroid 
therapy, and the work by Iqbal et al (1983), demonstrating for the 
first time the presence of AR in human HCC tissue, all suggest that 
HCC may be an androgen-responsive malignancy and hence that androgenic 
ablation many have some role to play in treatment. This study was 
conducted to establish whether castration could alter tumour 
development and growth in athymic mice inoculated with cells from a 
human HCC cell line, and to establish the AR status of human HCC cell 
lines and normal human liver tissue.
Nuclear AR were detectable both in specimens of normal adult liver and 
in tumour xenografts from all three human HCC cell lines studied. The 
finding of nuclear AR in normal adult liver is in contrast to the 
findings of Iqbal et al (1983), who found no evidence of nuclear or 
cytosolic AR in specimens from four normal livers, but is not 
surprising considering that androgenic steroids play an important role 
in the regulation of hepatic protein synthesis (Chan et al, 1978).
The differing results in the two studies may be explained by 
methodological differences. Dextran-coated charcoal, as used by Iqbal 
et al (1983), strips steroids from receptors, leading to an 
underestimation of AR concentration (Ekman et al, 1982). This problem 
is avoided by use of protamine sulphate precipitation (Davies et al, 
1977), which also has the advantages of avoiding the problems of 
metabolism and the precipitation of sex hormone binding globulin 
(Steggles and King, 1970). Nagasue et al (1985) have recently 
reported the presence of AR in normal human liver also, and both he 
and Ohnishi et al (1986) have been able to detect AR in human HCC
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tissue and, less frequently and at lower concentration, in some 
specimens of surrounding non-neoplastic hepatic tissue.
The nuclear AR concentrations demonstrated in this study are similar 
in both benign and malignant liver tissue and range from 235-550 fmol 
mg DNA. These values are considerably lower than the nuclear AR 
levels seen in rat ventral prostate but are similar to those seen in 
the normal, benign hypertrophic, and malignant human prostate (Davies,
1984). The presence of AR in liver tumour nuclei suggest a 
receptor-mediated system of androgen action. However, whether the low 
concentrations of AR observed are sufficient to promote molecular 
effects remains to be established, and whether the presence of AR 
represents a totally functional population and at what level requires 
more investigation. As current dogma implies a primary role of AR at 
the level of gene expression, the capacity of AR to bind DNA 
represents a preliminary determination of functional involvement. 
However, not all receptors in target cell nuclei associate with DNA in 
a form dissociated by high molarity salt solutions (Barrack et al, 
1977; Davies, 1983; Donnelly et al, 1984). In fact, the receptors 
which associate with nuclear components other than DNA may be more 
functional as regards stimulation of growth processes (Barrack et al,
1983). The detection of hepatic nuclear AR should not therefore be 
dismissed because of its low level of binding to DNA, and further work 
is needed to determine the exact role and biological significance of 
this finding.
Castration had no significant effect on the development and growth of 
HCC xenografts in athymic mice. However, there was an apparent trend 
which suggested that castration may result in fewer tumour
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developments and slower growth rates, and it is possible that a 
significant treatment difference may have been observed had a much 
larger number of animals been studied.
It is concluded that androgen receptors are present in low 
concentration in normal adult liver and in HCC cell lines. Though the 
exact biological significance of this finding is at present unclear, 
the presence of nuclear AR in established HCC cell lines, and the ease 
with which these lines can be grown as xenografts in athymic mice 
provide an excellent model for the further exploration of the effects 
of androgens and anti-androgenic drugs on HCC development and growth.
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CHAPTER EIGHT
IN VITRO AND IN VIVO TUMOUR LOCALISATION WITH A MONOCLONAL 
ANTIBODY DIRECTED AGAINST A MEMBRANE ANTIGEN ON THE 
HUMAN HEPATOCELLULAR CARCINOMA CELL LINE PLC/PRF/5
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ABSTRACT
A monoclonal antibody, designated K-PLC^, has been produced to a 
tumour-associated antigen on the cell membrane of the PLC/PRF/5 cell 
line. Using indirect immunofluorescence techniques, this antibody 
produced membrane staining of three HCC cell lines and positively 
stained 10 of 11 human HCC biopsy specimens.
125In vitro, I-labelled K-PLC^ bound specifically to PLC/PRF/5 cells, ■ 
as shown by competitive inhibition experiments. Antibody binding 
could be increased by prior incubation of PLC/PRF/5 cells with human 
lymphoblastoid interferon, though a significant increase was observed 
only at high IFN concentrations (1000 IU/ml).
Tumours derived from the PLC/PRF/5 cell line were grown in athymic
mice and groups of tumour-bearing animals were injected with either
125 125I-K-PLC^ or I-mouse IgG and then sacrificed at one, four or
seven days post injection. Bound radioactivity was counted in a
variety of solid organs and in blood. Tumour:liver ratios for K-PLC^
were greater than those for mouse IgG at each time point, the
differences being greatest on day four (ratio K-PLC^ 4.4 + 0.93, ratio
125mouse IgG 1.53 + 0.60, mean + SD, p<0.05). The amount of I-K-PLC^ 
bound was greater in the tumour than in any other solid organ, the 
differences again being maximal on day four. Blood pool radioactvity 
however, remained high throughout the study period.
Anti-HCC monoclonal antibodies such as K-PLC^ may be of value as 
immunodiagnostic and immunotherapeutic agents in HCC. The effects of 
IFNs on HCC tumour-associated antigen display merit further study.
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INTRODUCTION
The development of monoclonal antibody technology (Kohler and 
Milstein, 1975) has led to the detection and characterisation of 
so-called tumour-associated antigens on malignant cells (Lloyd, 1984). 
Such antibodies have now been produced to antigens associated with 
many different types of cancer and much current research in clinical 
oncology is devoted to the evaluation of these antibodies as possible 
immunodiagnostic and immunotherapeutic agents (Sikora et al, 1984; 
Dillman and Royston, 1984; Baldwin and Byers, 1985; Morgan and Foon, 
1986; Baldwin and Byers, 1986).
Monoclonal antibodies have recently been produced to HCC-associated 
cell membrane antigens (Carlson et al, 1985; Shouval et al, 1985; Hu 
et al, 1986). This chapter reports on the ability of one such 
antibody, K-PLC^, to react with human HCC cell lines and biopsy 
specimens, and describes in vivo tumour localisation studies performed 
in athymic mice with HCC tumour xenografts. In addition, experiments 
have been performed in vitro to determine whether human lymphoblastoid 
interferon can increase display of the antigen recognised by K-PLC^.
MATERIALS AND METHODS
Production and purification of K-PLC^
The production of K-PLC^ and the characterisation of the K-PLC^ 
antigen are fully described by Wiedmann et al (in press). To produce 
anti-HCC monoclonal antibodies, BALB/c mice were immunised by three 
intraperitoneal injections of 5 x 10 PLC/PRF/5 cells, repeated at 
three week intervals. Fourteen days after the last injection mice
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received an intravenous booster of 10 cells, and their spleens were 
removed four days later. Splenocytes were fused with the NS-1 mouse 
myeloma cell line using a modification of the polyethylene glycol 
(PEG) method of Kohler and Milstein (1975) in which splenocytes and 
myeloma cells at a ratio of 10:1 were incubated in 40% (w/v) PEG for 
seven minutes at 37°C. The suspension was then diluted in RPMI 1640 
medium (Gibco Ltd, UK) and plated out in HAT medium (Flow 
Laboratories, UK). When hybrid growth was apparent, supernatants were 
assayed by indirect immunofluorescence on PLC/PRF/5 cell suspensions 
(see below) and antibody-secreting clones were isolated by repeated 
limiting dilution on feeder cells. Of the several antibodies 
obtained, one, designated K-PLC^, was selected for further study.
This antibody is of IgG^ sub-type and reacts strongly not only with 
the PLC/PRF/5 cell line, but with several other carcinoma cell lines 
also, including those of cervix, bladder and colon (Table 8 (i)). The 
antigen recognised by K-PLC^ is of predominantly lipid composition, 
has a molecular weight of 30,000 daltons, and is immunologically 
distinct from HBsAg and AFP. K-PLC^ was grown in bulk either as 
ascites in pristane-primed BALB/c mice or as supernatants in tissue 
culture, and pure antibody was obtained by the passage of ascites or 
supernatant through protein A-sepharose columns (Pharmacia) as 
described by Ey et al (1978). The pH of the eluate was adjusted to 
8.0, antibody concentration estimated by the method of Lowry et al 
(1951), and adjusted to 1 mg/ml. Antibody aliquots were then stored 
at -70°C until used.
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Table 8 (i)
REACTIVITY OF K-PL^ WITH NEOPLASTIC CELL LINES OF NON-HEPATIC ORIGIN.
Indirect immunofluorescent staining is graded: - (negative),
+ (positive) and ++ (strong positive). Data from Wiedmann et al, (in 
press).
CELL LINE TISSUE OF ORIGIN
REACTIVITY WITH 
K-PLC-j^
HL60 Myeloid -
KM3 Myeloid -
Nalm6 B cell -
HT29 Colon +
HeLa Cervix +
RT4 Bladder (well differentiated) -
RT112 Bladder (moderately differentiated) +
FJ Bladder (anaplastic) ++
HCC cell lines
The PLC/PRF/5, SK-Hep-1 and Mahlavu cell lines were studied. Their 
source and culture conditions are described in detail in Chapter 4.
In vitro experiments were performed on cells from sub-confluent flasks 
48 hours following a change of culture medium.
Tissue specimens
Samples of tumour were obtained as needle (n = 9) or operative wedge 
biopsy specimens (n = 2) from patients with histologically proven HCC. 
Specimens were coated in OCT compound (Ames Co., UK), snap frozen in 
pre-chilled isopentane, and stored at -70°C until cryostat sections 
5 pm thick were cut for immunofluorescence studies.
Indirect immunofluorescence studies
Indirect immunofluorescence microscopy was performed on suspensions of 
each HCC cell line as follows. Cells were harvested by incubation and 
gentle shaking in EDTA and then pelleted by centrifugation. After 
washing three times in phosphate buffered saline (PBS) containing 1% 
bovine serum albumin (BSA) and 0.05% sodium azide (PBS-BSA), cells
c
were suspended in PBS-BSA at a concentration of 10 /ml and 50 pi 
incubated with 5 pi of K-PLC^ for five minutes. After three further 
washes, cells were resuspended in 50 pi of PBS-BSA and incubated with 
10 pi of fluorescein (FITC)-conjugated rabbit anti-mouse 
immunoglobulin (Dakopatts, Bucks, UK) for five minutes. After a final 
three washes, cells were resuspended in 50 pi of PBS-BSA and mounted 
on glass slides for examination using a Leitz microscope equipped with 
epifluorescent illumination.
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After washing 5 jam thick, air-dried, and unfixed cryostat sections of 
liver tissue for 10 minutes in PBS, sections were incubated with 
K-PLC^ diluted 1:20 with PBS for 30 minutes. Sections were then 
washed for 30 minutes in PBS and incubated for the same length of time 
with a 1:20 dilution of FITC-conjugated rabbit anti-mouse 
immunoglobulin. After a further 30 minute wash in PBS, sections were 
mounted in PBS containing 50% v/v glycerol and 0.3M 
diazobicyclo-octane, and examined with the Leitz microscope. Mouse 
IgG (Sigma Chemical Co Ltd, Dorset, UK) was also used as a first layer 
reagent in all immunofluorescence studies in order to provide a 
specificity control.
In vitro binding studies
125To determine whether I-K-PLC^ could bind specifically to PLC/PRF/5 
cells, competitive inhibition experiments were performed. K-PLC^ was 
iodinated by the Iodogen method to a specific activity of 1.0-1.3 
MBq/jig. PLC/PRF/5 cells were harvested, washed, and suspended at a
c
concentration of 10 /ml in PBS-BSA. Fifty jil aliquots of cell
suspension were added to 10.5 mm x 63.5 mm test tubes and then a
125
mixture of 50 jjI of a 1:20 dilution of I-K-PLC^ and 50 jil of
varying concentrations (from 0-20 jjg) of either unlabelled K-PLC^ or
mouse IgG was added. Tubes were vortex mixed and allowed to incubate
at room temperature for two hours. Following a further vortex mix, 75
jil aliquots of cell suspension were removed for centrifugation through
125silicone oil. Cell pellets were then assayed for bound I-K-PLC^ m
a '^-counter. Two hour incubation periods were chosen as previous
time course experiments had shown maximum antibody binding to HCC cell
125lines at this time (Figure 8 (i)). I-K-PLC^ binding to Mahlavu and 
SK-Hep-1 cells was also examined as above.
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Figure 8 (i)
THE KINETICS OF 125I-K-PLC. BINDING TO PLC/PRF/5 CELLS. A 1:20
125 4
dilution of I-K-PLC^ (approx. 62 ng) was incubated with 5 x 10
PLC/PRF/5 cells for the times shown. Cell separation was performed by
centrifugation through silicone oil. Data represent the mean HH SEM of
five experiments, each done in triplicate.
125I-K-PLC^ binding to PLC/PRF/5 cells was also examined after cells 
had been cultured in medium containing 0, 10, 100 or 1000 IU/ml of 
human lymphoblastoid interferon (Hu IFN-c<[Ly], IFN, Wellcome Research 
Laboratories, UK). After a 24 hour incubation in IFN, cells were
c.
washed and harvested as above, suspended at 10 /ml in PBS-BSA, and
50 jil aliquots of cell suspension were incubated with 50 jil of a 1:20 
125dilution of I-K-PLC. After a two hour incubation, cells were 
separated as above and bound radioactivity counted.
Tumour localisation studies
PLC/PRF/5-derived tumour xenografts were grown in athymic mice as
described in Chapter 4, and all localisation experiments were
2
performed in mice with tumours of base area 50-100 mm . K-PLC^ and
125mouse IgG were labelled with I by the Iodogen method to specific 
activities of approximately 1.0-1.3 and 1.2-1.4 MBq/pg respectively
and used on the day of preparation. Tumour-bearing mice were injected
125 125mtraperitoneally with 10 jig of either I-K-PLC^ or I-mouse IgG.
At one, four, and seven days post injection five mice in each antibody
group were sacrificed by exsanguination and specimens of tumour,
liver, spleen, kidney, stomach, small intestine, heart, lung and
skeletal muscle excised. After homogenisation and extensive washing
in PBS-BSA, specimens were weighed and bound radioactivity counted.
Biodistribution of isotope was expressed as a ratio of counts/min/g in
the tumour over counts/min/g in the organ in question.
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Examination for circulating K-PLC^ antigen in the sera of tumour- 
bearing athymic mice
Five athymic mice were allowed to develop large PLC/PRF/5-derived 
tumour xenografts. When tumours had reached a base area of greater 
than 350 mm , mice were killed by exsanguination and the sera removed 
and stored at -70°C until assayed. Sera from five athymic mice 
without tumours were used as a control. Competitive inhibition 
experiments were performed as described under in vitro binding 
studies, using 50 pi of increasing dilutions of mouse serum in place 
of unlabelled antibody, in order to determine whether mouse serum 
could inhibit the binding of I-K-PLC^ to PLC/PRF/5 cells. Each 
experiment was performed in triplicate.
RESULTS
Indirect immunofluorescence studies
K-PLC^ produced strong membrane staining of each of the three HCC cell 
lines examined (Figure 8 (ii)). In each case antigen display was 
heterogeneous in that not every cell stained positively. The 
percentage of cells in each cell line staining positively with K-PLC^ 
was approximately 90% for PLC/PRF/5 cells, and 80% and 65% 
respectively for the SK-Hep-1 and Mahlavu cell lines.
The results of the immunofluorescence studies on the 11 human HCC 
biopsy specimens examined are summarised in Table 8 (ii) and a 
representative example illustrated in Figure 8 (iii). Staining of HCC 
tissue was membranous and cytoplasmic in site and heterogeneous within
117
Figure 8 (ii)
INDIRECT IMMUNOFLUORESCENT STAINING OF THE CELL MEMBRANE OF PLC/PRF/5 
CELLS BY K - P L C 1 (x200).
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Figure 8 (iii)
INDIRECT IMMUNOFLUORESCENT STAINING OF A HUMAN HCC TISSUE SECTION BY 
K-PLC1 (xlOO).
tumours. One of the 11 tumours did not react with K-PLC^. This 
patient had a well-differentiated trabecular pattern HCC arising in a 
liver with cryptogenic cirrhosis.
In vitro binding studies
Unlabelled. K-PLGj^  inhibited the binding of ^I-K-PL^ to PLC/PRF/5
cells whereas the control mouse IgG did not (Figure 8 (iv)).
125I-K-PLC^ bound to each HCC cell line studied (Figure 8 (v)).
4
Approximately 1 ng of antibody bound to 5 x 10 PLC/PRF/5 cells and 
binding to SK-Hep-1 and Mahlavu cells was around 34% and 19% 
respectively, of that seen with PLC/PRF/5 cells.
Incubation of PLC/PRF/5 cells with IFN for 24 hours prior to the 
125addition of I-K-PLC^ increased antibody binding, suggesting that
IFN is capable of increasing the display of the K-PLC^ tumour-
associated antigen (Figure 8 (vi)). This effect was dose-related, but
reached statistical significance only at an IFN concentration of 1000
IU/ml (p = 0.032, Binomial test). More prolonged incubations with IFN 
125did not increase I-K-PLC^ binding further (data not shown).
125Location of HCC xenografts by I-K-PLC^ and examination of mouse 
sera for K-PLC^ antigen
K-PLC^ binds selectively to HCC tumour xenografts growing in athymic
mice. At all time points and for all solid organs studied, the
125tumour:tissue ratios of I-K-PLC^ were greater than 1.0, and far m
125excess of those seen with the control antibody, I-mouse IgG (Figure
1258 (vii)). Tumour:tissue ratios of I-K-PLC^ were greatest on day 
four, with a tendency to decline slightly by day seven post injection.
119
• 3
.C
2
2L.
Cou
o
o'
120
100
80
60
40
Mouse IgG
K-PLC
20
0.001 0.01 0.1 i.o
[added protein] (pig)
10 100
Figure 8 (iv)
125
I-K-PLCL TO PLC/PRF/5 CELLS BYCOMPETITIVE INHIBITION OF BINDING OF 
INCREASING QUANTITIES OF RADIO-INERT K-PL^ BUT NOT BY MOUSE IgG. 
Results are expressed as a percentage of the binding obtained in the 
absence of any radio-inert antibody and data represent the mean and 
standard deviation of 5 experiments each performed in triplicate.
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Figure 8 (v)
125
BINDING OF I-K-PLC. TO THE PLC/PRF/5, SK-HEP-l AND MAHLAVU CELL
125
LINES. 50 jil of a 1:20 dilution of I-K-PLC^ (approx. 62 ng of 
protein) was added to 5 x 10^ cells of each cell line for 2 hours. 
After centrifugation of the reaction mixture through silicone oil, the 
radioactivity bound to cell pellets was counted. Data represent the 
mean and standard deviation of 5 experiments each performed in
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Figure 8 (vi)
THE EFFECT OF HUMAN LYMPHOBLASTOID IFN ON 125I-K-PLC1 BINDING TO 
PLC/PRF/5 CELLS. PLC/PRF/5 cells were incubated in medium containing
IFN for 24 hours and then harvested and washed. 50 ul of a 1:20
125 4
dilution of I-K-PLC^ was added to 5 x 10 cells for 2 hours. Cells
were pelleted by centrifugation through silicone oil and bound
radioactivity counted. Results are expressed as a percentage of the
binding observed with cells incubated in the absence of IFN. Each of
the 6 experiments was performed in triplicate and bars represent mean
values.
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Figure 8 (vii) '
TUMOUR:TISSUE RATIOS FOR 125I-K-PLC1 (OPEN BARS) AND 125I-MOUSE IgG 
(SHADED BARS). Mice were injected intraperitoneally with 10 ug of 
either I-K-PLC^ (10-13 MBq) or I-mouse IgG (12-14 MBq) and 
sacrificed at either 1, 4 or 7 days post injection. Radioactivity was 
counted in homogenised and extensively washed tissues and the results 
expressed as a ratio of counts/min/g in the tumours over counts/min/g 
in the tissues in question. Results are expressed as the mean and 
standard deviation of experiments in 5 animals.
With a view to targeting antibodies to lesions in the liver,
tumour:liver ratios are obviously of importance. In this model system
125tumour:liver ratios for I-K-PLC^ were greater than those for 
125I-mouse IgG at all time points (Figure 8 (viii)). The differences
observed between the antibodies was greatest on day four (ratio K-PLC^
4.4 + 0.93, ratio mouse IgG 1.53 + 0.60, mean + SD, p<0.05, Wilcoxon's
rank sum test), and remained significantly different at day seven.
125Tumour:blood ratios for I-K-PLC^ were much lower than any of the
tumour:solid organ ratios (Figure 8 (vii)). At 24 hours the
tumour:blood ratio was 0.57, indicating the presence of almost twice
125as much free circulating I-K-PLC^ as that bound to the tumour. By
day four post injection the tumour:blood ratio had risen to 1.90 
125(p<0.05 vs I-mouse IgG, Wilcoxon's rank sum test) and at day seven 
the ratio had declined slightly to 1.81.
Gamma camera pictures of an athymic mouse with an HCC xenograft taken
125at one and four days post injection with I-K-PLC^ are shown m  
Figure 8 (ix).
The sera of mice with large PLC/PRF/5-derived tumour xenografts did
125
not competitively inhibit the binding of I-K-PLC^ to PLC/PRF/5 
cells in vitro, suggesting that there is no significant secretion of 
K-PLC^ antigen from tumour xenografts into mouse serum (data not 
shown).
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Figure 8 (viii)
TUMOUR:LIVER RATIOS FOR 125I-K-PLC1 AND 125I-MOUSE IgG. Methodology 
is similar to that described in Figure 8 (vii). Each result is the 
mean + standard deviation of the values obtained in 5 animals. The 
differences between the two antibodies is statistically significant on 
days 4 and 7 post injection.
Figure 8 (ix)
GAMMA CAMERA PICTURES OF AN ATHYMIC MOUSE WITH A PLC/PRF/5-DERIVED
TUMOUR XENOGRAFT GROWING OVER THE RIGHT SHOULDER.
Pictures were taken with a gamma camera fitted with a pin-hole
collimator at 1 (A) and 4 (B) days following an IV injection of 10 yig 
12 5
of I-K-PLC . The animal was sedated with intraperitoneal diazepam
125
prior to examination and thyroid uptake of I blocked by the prior 
addition of potassium iodide to the drinking water. On day 1 there is 
no obvious specific uptake of antibody by the tumour and the small 
area of increased uptake in the tail is due to tissue extravasation 
following tail vein injection. By day 4 there has been a decline in 
blood-pool radioactivity, allowing specific antibody uptake by the 
tumour to become clearly visible.
DISCUSSION
Wiedmann et al (in press) have shown that K-PLC^ does not react with 
non-malignant hepatocytes, reacts only very weakly with vascular 
endothelium and some secretory epithelia, including bile duct 
epithelium, but reacts very strongly with a variety of carcinoma cell 
lines and tissue sections. As with almost all such antigen systems, 
the antigen recognised by K-PLC^ is therefore tumour-associated and 
not tumour-specific.
This study has demonstrated abundant but heterogeneous K-PLC^ antigen 
display by three HCC cell lines and by 10 of 11 HCC tumour specimens 
and it is therefore possible that K-PLC^ may be of some use in 
immunocytohistochemistry, and enable the diagnosis of HCC to be made 
more easily from fine needle aspiration cytology specimens.
Secretion of K-PLC^ antigen into the sera of mice with large HCC 
tumour xenografts was not detected in competitive inhibition 
experiments. While this precludes the use of this system as a 
potential serological tumour marker for HCC, this phenomenon may be 
advantageous in the setting of tumour imaging or drug targeting with 
monoclonal antibodies, as the reaction of secreted antigen with 
injected antibody in the circulation may theoretically stop antibody 
from reaching the tumour target, prolong antibody retention in serum, 
and lead to immune complex formation. These potential drawbacks, 
which may not be as great a problem in reality as would be expected 
theoretically (Dillman and Royston, 1984), are avoided by using 
antibodies such as K-PLC^ which react with non-secreted 
tumour-associated antigens.
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125The tumour localisation experiments suggest that I-K-PLC^ binds 
preferentially to HCC tumour xenografts rather than to other solid 
tissues and that tumour:non-tumour antibody ratios are greatest four 
days after antibody injection, a time period similar to that noted by 
other authors (Moshakis et al, 1981; Epenetos et al, 1982).
Tumour:liver ratios were however rather lower than hoped for, and 
blood-pool radioactivity was high throughout the study period.
Methods which can increase target antigen display by the tumour or 
enhance unbound antibody clearance from the circulation should improve 
tumour:non-tumour antibody ratios and potentially enhance the value of 
monoclonal antibodies as immunodiagnostic or therapeutic agents.
Interferons may increase tumour-associated antigen display (Greiner et 
al, 1984) and therefore be of some benefit in this regard. In vitro, 
human lymphoblastoid IFN increased K-PLC^ antigen display by PLC/PRF/5 
cells and further studies are required to determine whether IFNs can 
affect K-PLC^ antigen display in vivo. Clearance of circulating 
unbound radiolabelled antibody can be enhanced by the administration 
of a liposomally entrapped second antibody against the first antibody 
(Begent et al, 1982). While this technique could prove advantageous 
for targeting to peripheral tumours, the removal of liposomes by the 
reticuloendothelial system could well complicate the targeting of 
lesions within the liver. Of greater application with respect to 
liver lesions may be the use of F(ab) or F(ab)2 antibody fragments. 
Antibody is removed rapidly from the circulation after the elimination 
of its Fc piece (Hopf et al, 1976) and several studies have now 
demonstrated improved tumour targeting when F(ab) (Larson et al, 1983; 
Carlson et al, 1985) or F(ab)2 fragments (Houston et al, 1980; Bate et 
al, 19&0; Wahl et al, 1983) are used in place of intact antibody.
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Despite the fact that a variety of tumours can be successfully imaged 
by radiolabelled monoclonal antibodies (for review see Baldwin and 
Byers, 1985) it is unlikely that this technique will approach the 
diagnostic accuracy of currently available imaging modalities in the 
near future. Probably the most important use of anti-tumour 
monoclonal antibodies in the future will be to specifically target 
either drugs, radioisotopes or cellular toxins to tumours and 
therefore provide a highly selective and hopefully non-toxic means of 
killing tumours and their metastases. Such therapy is at an early 
stage of development, and of the many potential problems of antibody 
therapy (Embleton, 1987), the problems of antigenic heterogeneity and 
the antigenicity of murine monoclonal antibodies in man particularly 
stand out.
Antigenic heterogeneity, as demonstrated by the K-PLC^ antigen in this 
study, is common among tumour-associated antigens (Edwards, 1985). It 
has previously been shown that the anti-tumour response to passively 
administered monoclonal antibody is dependent on the level of target 
antigen display by the tumour in question, and it has been suggested 
that a single passively administered monoclonal antibody is unlikely 
to eradicate solid tumours completely (Capone et al, 1984). To 
overcome this potential problem it may be necessary to administer 
antibody combinations (for example K-PLC^ plus other anti-HCC 
(Shouval et al, 1985; Carlson et al, 1985; Hu et al, 1986) or anti- 
AFP antibodies (Tsukada et al, 1985)) in order to reach all the cells 
in a given tumour, or alternatively a single monoclonal antibody 
linked to a high energy -radiation emitter such as Iodine may be 
able to destroy cells bearing the target antigen plus all cells around
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it for many cell diameters. Similarly,the problem of the antigenicity 
of murine antibodies, which may lead to allergic reactions and to 
reduced antibody effectiveness, may not be as great in practice as 
expected in theory (Schroff et al, 1985), and may be overcome in the 
future by the development of human monoclonal antibodies (Sikora,
1984).
Encouraged by the fact that the problems of monoclonal antibody 
therapy in man may be soluble in the near future, and by recent work 
demonstrating that the development of HCC tumour xenografts in athymic 
mice can be inhibited by monoclonal anti-HBs (Shouval et al, 1982), 
and that the growth of established HCC xenografts can be inhibited in 
these animals either by monoclonal anti-HBs linked to the plant toxin 
ricin (Oladapo et al, 1984) or by a drug such as daunorubicin 
conjugated to anti-AFP antibodies (Tsukada et al, 1985), the 
immunotherapeutic potential of native, isotope and ricin-conjugated 
K-PLC^ is currently being evaluated in the athymic mouse model.
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CHAPTER NINE
RECOMMENDATIONS FOR FURTHER STUDIES AND CONCLUDING REMARKS
125
Like most pieces of research, this thesis has perhaps raised more 
questions than it has answered. In the light of my findings I have 
listed below further studies which I think are required.
FURTHER STUDIES 
Chapter 1
HCC, as it is seen in the United Kingdom, is clearly diagnosed late in 
its natural history, and curative resection is rarely possible. It 
remains to be determined whether prospective screening of the British 
cirrhotic population, using a combination of repeated serum AFP 
measurements and real-time hepatic ultrasonography, is effective in 
diagnosing asymptomatic HCC patients with small tumours at a stage 
when curative surgery is possible.
Liver cell dysplasia was frequently observed in British HCC patients, 
and in some cases this preceeded tumour development by many years. It 
would be of interest to determine the exact frequency of liver cell 
dysplasia in the British cirrhotic population and to prospectively 
follow such a group to determine whether patients with dysplasia are 
at greater risk of tumour development than those without.
Further studies are needed to more accurately determine the 
relationship between HBV infection and HCC development. The exact 
frequency with which integrated HBV-DNA sequences can be detected in 
the tumours of serum HBsAg positive and negative patients requires to 
be determined more accurately in the British HCC population, as so far
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it has been possible to study only a relatively small number of 
patients. The molecular mechanisms whereby HBV-DNA integration may 
eventually result in cellular transformation remain to be fully 
elucidated.
Chapters 2 and 3
Much of the literature on HCC treatment is unsatisfactory and many 
questions remain unanswered. As liver transplantation becomes more 
widely available, its role in the treatment of patients with 
non-resectable lesions requires to be determined. Controlled clinical 
trials are needed to determine whether intra-arterial drug 
administration is better than simple intravenous treatment with the 
same agent. Similarly, controlled trials are needed to examine the 
role of "lipiodolised" drug treatment in HCC, and the efficacy of 
several combinations of therapeutic modalities could be usefully 
examined.
A phase III study is needed to compare doxorubicin and mitozantrone in 
the treatment of inoperable HCC patients.
Chapters 5 and 6
A comparison of the effects of each IFN class ( c< / j? and *7f) on the
in vitro and in vivo growth of HCC cell lines would be of interest, as
would studies comparing their effects on tumour 2,5A synthetase 
activity and HLA class I glycoprotein display. Similarly the effects 
of a particular IFN class on the growth of several different HCC cell
lines should be studied, in order to determine whether there are any
important differences in IFN sensitivity between cell lines.
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Extensive phase I and phase II studies of each IFN class need to be 
undertaken in HCC patients before the role of IFN in HCC treatment can 
be determined with any certainty. A study of the effects of chronic 
low dose IFN therapy on immunological parameters in HCC patients would 
be of some interest, and further studies are needed to determine the 
pathogenesis of the reduced NK cell activity in HCC patients.
Chapter 7
The frequency with which nuclear androgen receptors may be found in 
samples of normal adult liver, cirrhotic liver, and HCC tissue remains 
to be accurately determined. The biological significance of the 
presence of nuclear AR in these sites requires elucidation. If in 
vitro studies suggest that the low concentrations of AR present in HCC 
tumour xenografts are sufficient to promote molecular effects such as 
the transcription of specific messenger RNA sequences, then further 
studies in large numbers of xenografted animals, in which the hormonal 
environment is manipulated medically, would be of interest.
Chapter 8
This chapter perhaps raises more questions than any of the others.
The value of K-PLC^ as an immunocytochemical reagent for the diagnosis 
of HCC from fine needle aspiration cytology specimens should be 
determined. Immunoscintigraphic studies with radiolabelled K-PLC^ are 
currently under way in HCC patients and their results should indicate 
whether K-PLC^ is of value in the visualisation of tumours and their 
metastases.
In vitro studies are required to determine the effects of each IFN 
class on K-PLC^ expression by HCC cell lines. The effect of in vivo
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IFN administration of K-PLC^ antigen display by HCC tumour xenografts 
should be examined, and, as pilot studies of IFN therapy in HCC 
patients are now underway, it may be possible to examine this 
phenomenon in liver biopsy specimens taken before and during IFN 
treatment.
The immunotherapeutic potential of native, isotopically labelled, and 
ricin-conjugated K-PLC^ is currently being explored in athymic mice 
with HCC tumour xenografts.
CONCLUSIONS
While the immediate outlook for HCC patients undoubtedly remains 
gloomy, there are now several rays of hope on the horizon.
The development of effective immunisation schedules against 
perinatally acquired HBV infection brings the exciting prospect of 
tumour prevention through vaccination a step closer to reality in 
areas of high HCC incidence. The application of such schedules must 
become a public health priority in these regions, and the development 
of cheap genetically engineered and chemically synthesised HBV 
vaccines will hopefully bring the cost of immunisation within the 
reach of the many Third World countries involved. As with all 
disease, prevention is better than cure.
In areas of low HCC incidence, where HBV infection is much less often 
implicated as an aetiological factor in hepatic carcinogenesis, there 
is little prospect of significantly reducing HCC incidence by 
vaccination against the HBV. In these areas in particular, screening
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methods must be developed which allow the detection of small 
resectable tumours in asymptomatic patients. The need for such 
techniques is clearly emphasised by the finding in British HCC 
patients of a median duration of survival of only seven weeks from 
diagnosis (Chapter 1). The value of screening patients with chronic 
liver disease by a combination of repeated serum AFP estimation and 
real-time hepatic ultrasonography has been established in the Asian 
population, and this method should now be evaluated as a matter of 
some urgency in other regions. It should be remembered however, that 
at least in the United Kingdom, a significant proportion of patients 
with chronic liver disease present de novo with HCC and will escape 
screening (Chapter 1).
There will therefore continue to be an urgent need for new and more 
efficacious medical therapies for patients with inoperable HCC. 
Progress in this field has been much less dramatic than that seen in 
other areas. This seems likely to change in the near future however, 
as exciting new treatment modalities, several of which act wholly or 
partly by modifying host biological responses, are evaluated. In this 
thesis I have explored three areas of therapeutic opportunity. 
Preliminary experiments involving androgenic manipulation did not 
prove as therapeutically promising as had been hoped. However both 
interferon therapy and immunotherapy with monoclonal antibodies offer 
real hope for future treatment. These materials are now available in 
relative abundance, and the next few years will hopefully see them 
advance from the laboratory to extensive evaluation in the clinical 
setting.
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APPENDIX
The findings of this thesis have been presented at national and 
international meetings in Europe and the USA and published in abstract 
form as listed below:
J Hepatol 1984; 1 (Suppl 1): A96
Gut 1984; 25: A1131
Gut 1985; 26: A561
Hepatology 1985; 5: A78
Gut 1986; 27: A616
Gut 1986; 27: A1265
Scot Med J 1986; 31: 263-264
Much of the work has either been published in full or is currently in 
press, and the remainder has been submitted for publication. Those 
papers already published or in press are listed below and reprints may 
be found in the inside back pocket of the thesis.
Dunk AA, Scott SC, Johnson PJ, Melia WM, Lok ASF, Murray-Lyon I, 
Williams R, Thomas HC. Mitozantrone as single agent therapy in 
hepatocellular carcinoma: a phase II study.
J Hepatol 1985; 1: 395-404.
Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid 
interferon: in vitro and in vivo studies in hepatocellular carcinoma.
J Hepatol 1986; 2: 419-429.
132
Dunk AA, Brown D, Wiedmann K, Thomas HC. In vitro and in vivo tumour 
localisation with a monoclonal antibody directed against a membrane 
antigen on the human hepatocellular carcinoma cell line PLC/PRF/5.
J Hepatol 1987; 4: 52-61.
Dunk AA, Spiliadis H, Sherlock S, Fowler MJF, Monjardino JP,
Scheuer PJ, Karayiannis P, Thomas HC. Hepatocellular carcinoma and 
the hepatitis B virus: a study of British patients.
Q J Med 1987; 62: 109-116.
Dunk AA, Thomas HC. The treatment of hepatocellular carcinoma. 
Aliment Pharmacol Therap (in press).
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